US Pat. No. 10,428,189

PROCESS AND COMPOSITION FOR WELL DISPERSED, HIGHLY LOADED COLOR MASTERBATCH

CHROMA COLOR CORPORATION,...

1. A process for making a masterbatch composition comprising:providing an additive mixture including a colorant and an optional additive component or components to a primary feed;
melting a thermoplastic and providing the melted thermoplastic to a secondary feed that is physically separated from the primary feed;
combining the secondary feed with the primary feed and extruding the resultant mixture to form a masterbatch composition having greater than 45 wt. % of the additive mixture; and
wherein, upon combining the primary and secondary feeds, a weight ratio of primary to secondary feed is greater than 60:40.
US Pat. No. 10,429,728

MASK BLANK SUBSTRATE, SUBSTRATE WITH MULTILAYER REFLECTION FILM, TRANSMISSIVE MASK BLANK, REFLECTIVE MASK BLANK, TRANSMISSIVE MASK, REFLECTIVE MASK, AND SEMICONDUCTOR DEVICE FABRICATION METHOD

HOYA CORPORATION, Tokyo ...

1. A production method of a mask blank substrate for use in lithography, the method comprising:surface-treating a main surface of the substrate so as to satisfy a relational equation of (BA70?BA30)/(BD70?BD30)?350 (%/nm) of the main surface of the substrate, and the main surface of the substrate having a maximum height (Rmax)?1.2 nm in a relation between a bearing area (%) and a bearing depth (nm) obtained by measuring, with an atomic force microscope, an area of 1 ?m×1 ?m in the main surface on a side of the substrate where a transfer pattern is formed, wherein BA30 is defined as a bearing area of 30%, BA70 is defined as a bearing area of 70%, and BD70 and BD30 are defined to respectively represent bearing depths for the bearing area of 30% and the bearing area of 70%; and
inspecting defects of the main surface of the substrate using inspection light having a wavelength region of 150 nm to 365 nm or inspection light having a wavelength region of 0.2 nm to 100 nm.
US Pat. No. 10,428,190

PROCESSES FOR DESIGNING CROSS-LINKABLE POLYCARBONATES AND ARTICLES FORMED THEREFROM

SABIC GLOBAL TECHNOLOGIES...

1. A process for preparing an article that has a high probability of passing UL94 V0 test, the process comprising:(A) providing a polymeric composition to be exposed to a dosage (D) of UVA radiation, wherein the polymeric composition comprises:
(i) a cross-linkable polycarbonate resin including repeating units derived from a dihydroxybenzophenone;
(ii) a flame retardant; and
(iii) optionally one or more polymeric base resins;
(iv) wherein the cross-linkable polycarbonate resin contains a molar percentage of the dihydroxybenzophenone (MOL %); and
(v) wherein the polymeric composition has:
(a) a molecular weight increase of polymeric components therein after exposure to UV radiation (MW_I in gram/mol)
(b) a melt flow rate (MF), MF being measured in cubic centimeter per 10 minutes according to ASTM D1238-13, 1.2 kg load, 300° C. temperature, 360 second dwell, and
(c) a weight percentage of the cross-linkable polycarbonate resin (WP);
(B) forming an article from the polymeric composition; and
(C) exposing the formed article to the dosage;wherein D, MOL %, MW_I, MF, and WP are determined based on a flame performance equation as follows:Sqrt(V0_Avg)=?0.62315+(9.21942×10?3×WP)+(0.041498×D)+(4.34876×10?5×MW_I)+(6.55546×10?3×MOL %)+(0.089017×MF)+(9.87122×10?4×WP×D)?(4.36994×10?6×WP×MW_I)?(2.43440×10?3×WP×MOL %)+(2.08870×10?3×WP×MF)?(4.40362×10?6×D×MW_I)?(2.32567×10?3×D×MOL %)?(3.75290×10?3×D×MF)+(2.05611×10?5×MW_I×MF)+(5.61409×10?3×MOL %×MF)+(2.98567×10?9×(MW_I)2)+(6.17229×10?3×(MOL %)2)?(0.017115×(MF)2)wherein the article has an average V0(V0_Avg) that is the average of:(i) the probability of a first time pass in a UL94 V0 test at a thickness of 1.2 mm after UV exposure measured after 2 days of aging at room temperature, and
(ii) the probability of a first time pass in a UL94 V0 test at a thickness of 1.2 mm after UV exposure measured after 7 days of aging at 70° C.; andwherein V0 _Avg is at least 0.7; andwherein D is measured in J/cm 2 of UVA radiation.
US Pat. No. 10,428,446

WOVEN FLAME-RESISTANT GARMENT FABRIC, AND GARMENT MADE THEREFROM

1. A woven flame-resistant garment fabric, the fabric comprising warp yarns that extend in a longitudinal or warp direction and fill yarns that extend in a width direction of the fabric, the warp and fill yarns comprising at least about 30 wt. % inherently flame-resistant fibers, the fabric being a single-layer fabric woven from a plurality of warp yarn groups consecutively arranged across the width direction in a recurring pattern, each warp yarn group consisting of a plurality of adjacent consecutively arranged warp yarns,wherein at least one warp yarn in each warp yarn group is woven with the fill yarns in a plain (1/1) weave and at least one warp yarn in each warp yarn group is woven with the fill yarns in one or more non-plain weaves each selected from the group consisting of 1/2, 2/1, 2/2, 1/3, and 3/1, and
wherein approximately half of the warp yarns in the fabric are woven with the fill yarns in a plain (1/1) weave and the remaining warp yarns in the fabric are woven with the fill yarns in said one or more non-plain weaves, in an alternating fashion.
US Pat. No. 10,428,191

CHITIN NANOWHISKER COMPOSITES AND METHODS

BOCO Technology Inc., To...

1. A product comprising a plurality of particles of polycarbonate substantially coated with a chitin nanowhisker gel.
US Pat. No. 10,428,193

POLYURETHANE PREPREGS WITH CONTROLLABLE TACK

Evonik Degussa GmbH, Ess...

1. Process for producing a laminate, comprising the steps of:a) providing a reactive composition comprising at least the following constituents:
at least one blocked isocyanate hardener,
at least one binder which is a polyol compound having an OH functionality of 3 to 6 and which has at least one polar functional group selected from an ester, carbonate, amide, urethane, urea, thioester or thiocarbonate functionality;
at least one co-binder which is an epoxy resin,
at least one hardener which corresponds to the co-binder and is selected from the group comprising the following substance classes: aliphatic polyamines, cycloaliphatic polyamines, polyetheramines, polymercaptans or polyamidoamines, polycarboxylic acids, polycarboxylic anhydrides;
b) providing fibres;
c) coating the fibres with the reactive composition;
d) exposing at least the reactive composition to heat to perform a first crosslinking reaction, in the course of which hardener and binder are converted to a thermoplastic polymer, the fibres being embedded into the thermoplastic polymer;
e) obtaining a prepreg comprising the thermoplastic polymer with the fibres embedded therein,
characterized in that
the reactive composition is provided in such a way that the glass transition temperature of the thermoplastic polymer measured in the second heating curve at 10 K/min according to the DSC method as defined in DIN 53765 is above 30° C., through
i) use of a polyol compound or a mixture of a number of polyol compounds as binder, the OH number measured according to DIN 53 240-2 or mean OH number of which is above 300 mg KOH/g,
and/or
ii) choice of the proportion of hardener which corresponds to the co-binder in the reactive composition at greater than 2% by weight, based on the total solids content of the reactive composition,
characterized in that the fibres are provided continuously from a roll as a textile fabric, in that the textile fabric is coated continuously with the reactive composition, and in that the textile fabric coated with the reactive composition is exposed continuously to heat to perform the first crosslinking reaction, such that the thermoplastic polymer with the fibres embedded therein forms a continuous prepreg in the form of a strip which is cut into individual sections and the individual sections are layered in a stack and pressed to form a laminate.
US Pat. No. 10,426,146

NON-HUMAN ANIMALS HAVING A HUMANIZED SIGNAL-REGULATORY PROTEIN GENE

REGENERON PHARMACEUTICALS...

1. A rodent whose genome comprises a humanized SIRP? gene at an endogenous rodent SIRP? locus, wherein the humanized SIRP? gene(i) comprises exon 1 of a rodent SIRP? gene, exons 2, 3 and 4 of a human SIRP? gene, and exons 5, 6, 7 and 8 of the rodent SIRP? gene,
(ii) is operably linked to a rodent SIRP? promoter at the endogenous rodent SIRP? locus, and
(iii) expresses in the rodent a humanized SIRP? protein comprising an extracellular portion of the human SIRP? protein encoded by the human SIRP? gene and an intracellular portion of the rodent SIRP? protein encoded by the rodent SIRP? gene; and
wherein the rodent is a rat and is homozygous for the humanized SIRP? gene.
US Pat. No. 10,427,938

METHOD AND DEVICE FOR DETECTING CELLULAR TARGETS IN BODILY SOURCES USING CARBON NANOTUBE THIN FILM

UNIVERSITY OF LOUISVILLE ...

1. A method of fabricating a sensor for detecting cellular targets in a bodily source, the method comprising:forming a thin film of carbon nanotubes (CNT's) on a carrier using vacuum filtration;
mechanically bonding the thin film to a dielectric layer on a semiconductor substrate;
separating the thin film from the carrier;
patterning the thin film to form a biofunctional pad; and
depositing a plurality of conductive contacts on the substrate, with at least a portion of each conductive contact overlapping and electrically coupled to the thin film, wherein after forming the thin film, the method additionally comprises the step of altering a surface of the thin film or the biofunctional pad, to provide the biofunctional pad with a hydrophilic surface which lowers the density of the CNTs on the portion of the surface that was altered.
US Pat. No. 10,429,733

LOW TEMPERATURE BAKING ADAPTED RESIST INK

DIC GRAPHICS CORPORATION,...

1. A resist ink adaptable to low temperature baking, comprising a polyester resin, a titanium oxide, and an organic silicon compound,wherein the titanium oxide is contained in an amount of 2.5 to 30% by weight based on the total amount of the resist ink.
US Pat. No. 10,426,147

INSECT MUSCLE ACTIN PROMOTER

Oxitec Limited, Abingdon...

1. A polynucleotide expression system, comprising:a polynucleotide sequence encoding a fluorescent marker; and
an insect muscle actin promoter comprising a nucleic acid sequence that is at least 95% identical as the nucleic acid sequence set forth in SEQ ID NO: 1, 5, or 6, operably linked to the polynucleotide sequence.
US Pat. No. 10,427,940

APATITE PRETREATMENT

BIO-RAD LABORATORIES, INC...

1. A method of treating a ceramic hydroxyapatite solid surface prior to first use in a chromatographic procedure, the method comprising:(a) providing a ceramic hydroxyapatite solid surface, wherein the ceramic hydroxyapatite solid surface has not been used in any chromatographic procedure and has not previously been contacted with any sample;
(b) contacting the ceramic hydroxyapatite solid surface with a phosphate buffered solution at a pH of at least about 6.5; and then
(c) contacting the ceramic hydroxyapatite solid surface obtained in step (b) with a solution having a hydroxide; and then
(d) purifying protein from a sample with the ceramic hydroxyapatite solid surface obtained in step (c).
US Pat. No. 10,428,196

CURABLE NANO-COMPOSITES FOR ADDITIVE MANUFACTURING

Schmutz IP, LLC, Lawrenc...

1. A curable liquid nano-composite for use with a jetable piezo head device for additive manufacturing of a semi-conductive component, the nano-composite comprising:one or more cross-linkable diacrylates and/or triacryclates present in an amount from about 10-50 wt % based upon the total weight of the nano-composite;
a photo-initiator; and
an organic nanoparticle,
wherein the curable liquid nano-composite is configured for use in said jetable piezo head device to produce said semi-conductive component.
US Pat. No. 10,429,736

METHOD OF MAKING A FLEXOGRAPHIC PRINTING PLATE

MacDermid Graphics Soluti...

1. A method of making a flexographic printing plate is provided, said method comprising:a) providing a liquid photocurable composition in a reservoir, wherein the photocurable composition comprises:
i) a binder resin;
ii) monomers;
iii) a photoinitiator; and
iv) a polymerization inhibitor;
wherein the reservoir contains a transparent bottom, and wherein actinic radiation is capable of shining through the transparent bottom; and
b) providing a carrier plate comprising a substrate and a cured layer of photopolymer on said substrate wherein the cured layer of photopolymer provides a surface on which a flexographic printing plate is formed, wherein the reservoir is below the carrier plate;
c) bringing the cured layer of photopolymer into contact with the liquid photocurable composition in the reservoir;
d) selectively providing actinic radiation beneath the transparent bottom of the reservoir in a pattern that corresponds to raised relief structures to be formed on the cured layer of photopolymer, wherein the radiation crosslinks and cures areas of the liquid photocurable composition in the reservoir;
e) moving the carrier plate away from the reservoir while the actinic radiation continuously crosslinks and cures the photocurable composition to form a flexographic printing plate, wherein raised features of the flexographic printing plate are formed on the cured layer of photopolymer on the carrier plate simultaneously as the carrier plate is withdrawn from the reservoir.
US Pat. No. 10,428,199

POLYESTER-ETHER RESIN BLENDS

Trevira Holdings GMBH, (...

1. A composition for blow-molding articles comprising:a) ?80-99.5 parts by weight of polyester;
b) a copolyester-ether, wherein the copolyester-ether comprises one or more polyether segments having a number-average molecular weight of between 200 to 5000 g/mol;
c) a transition metal-based oxidation catalyst, wherein the transition metal is selected from the group consisting of cobalt, manganese, copper, chromium, zinc, iron or nickel, and wherein the transition metal based oxidation catalyst is present in an amount of ?2000 to <6000 ppm, on basis of the weight of the transition metal in the composition;
d) an alkali metal compound, and
e) an alkaline earth metal compound;wherein the weight ratio of the transition metal-based oxidation catalyst to the alkaline earth metal compound, of the weight of the transition metal and the alkaline earth metal, is from 50:1 to 1:50, and the weight ratio of the alkali metal compound to the alkaline earth metal compound, on basis of the weight of the alkali metal and the alkaline earth metal, is from 20:1 to 1:20; and wherein the intrinsic viscosity of said composition is at least 0.4 dL/g.
US Pat. No. 10,428,455

PLASMA TREATMENTS FOR COLORATION OF TEXTILES, FIBERS AND OTHER SUBSTRATES

The North Face Apparel Co...

1. A method of treating a substrate, comprising:providing a substrate comprising a textile having a generally sheet or planar form or a substrate comprising a fiber or yarn form;
providing a colorant to be set at the surface of the substrate; and
at about atmospheric pressure, subjecting the substrate and the colorant to reactive species from a plasma generated by an atmospheric plasma apparatus until the colorant affixes to the substrate via chemical bonding to a desired color, wherein the energy of the plasma is sufficient to overcome bond energies to cause permanent bonding of the colorant on the substrate, without the substrate being immersed in a dye bath and without subjecting the substrate and colorant to a separate thermal fixation step, and wherein the affixing of the substrate provides a wash durable coating on the substrate and the change of color without negatively affecting the bulk properties of the substrate.
US Pat. No. 10,429,738

FILTRATION FILTER, FILTRATION METHOD, PRODUCTION METHOD OF PURIFIED LIQUID CHEMICAL PRODUCT FOR LITHOGRAPHY, AND METHOD OF FORMING RESIST PATTERN

TOKYO OHKA KOGYO CO., LTD...

1. A filtration filter used for filtering a liquid chemical for lithography, the filtration filter comprising a polyimide resin porous membrane having a porous structure in which adjacent spherical cells are mutually communicating so as to form a flow path through which the liquid chemical can flow from one side of the membrane to the other side of the membrane, said membrane having a total porosity of 60 to 90% by weight, wherein the average pore diameter of all pores in the polyimide resin porous membrane is from 100 to 2000 nm.
US Pat. No. 10,427,945

ION SIEVE MATERIAL, AND METHODS OF PREPARING AND USING THE SAME

Shenzhen Donglihua Techno...

3. A method of using an ion sieve material, comprising the steps of:providing a molten liquid salt compound to be purified; and adding an ion sieve material to the molten liquid salt compound, and reacting at a temperature that is above the melting temperature of the liquid salt compound; and removing the ion sieve material after the concentration of the impurity metal ions to be purified in the molten liquid salt compound falls within a preset range; wherein the ion sieve material comprises, based on the weight of the ion sieve material, 15-55% by weight (wt %) of SiO2, 5-50 wt % of an auxiliary material, and 15-48 wt % of at least one functional metal oxide, wherein the metal in the functional metal oxide is a monovalent and/or divalent metal.
US Pat. No. 10,428,201

PLASTICIZER COMPOSITIONS AND METHODS FOR MAKING PLASTICIZER COMPOSITIONS

Dow Global Technologies L...

1. A plasticizer composition, comprising:an epoxidized fatty acid alkyl ester, wherein said epoxidized fatty acid alkyl ester has
(i) an APHA color value from at least 1 to less than 15;
(ii) a triepoxide content from at least 6.5 weight percent to less than 8 weight percent, based on the entire weight of said epoxidized fatty acid alkyl ester, wherein the triepoxide is an epoxidized C18 fatty acid alkyl ester molecule having three epoxide groups on its alkyl tail;
(iii) an oxirane oxygen content of at least 5 grams oxirane per 100 grams of epoxidized fatty acid alkyl ester;
(iv) a fatty acid dimer content greater than 0.8 weight percent based on the entire weight of said epoxidized fatty acid alkyl ester; and
(v) an iodine value from at least 1 gram to less than 5 grams per 100 grams of epoxidized fatty acid alkyl ester.
US Pat. No. 10,428,202

ELASTOMER CONTAINING COMBINATION OF TRIS(NONYL PHENYL) PHOSPHITE AND TETRAMETHYLETHYLENEDIAMINE, PREPARATION AND COMPOSITIONS AND ARTICLES OF MANUFACTURE THEREOF

1. An elastomer composite comprised of at least one diene-based elastomer containing an antioxidant comprised of a combination of tris(nonyl phenyl) phosphite (TNPP) and tetramethylethylene diamine (TMEDA) in a weight ratio of TNPP to TMEDA in a range of from about 4/1 to about 50/1.
US Pat. No. 10,428,204

POLYOLEFIN COMPOSITIONS FOR BUILDING MATERIALS

BASF SE, Ludwigshafen (D...

1. An extruded article comprising a polyolefin substrate having incorporated therein one or more additives comprising:about 0.10 to about 2.5 weight percent, in total, of one or more ultraviolet light absorbers selected from the group consisting of hexadecyl 3,5-di-tert-butyl-4-hydroxybenzoate and 2,4-di-tert-butylphenyl 3,5-di-tert-butyl-4-hydroxybenzoate;
about 0.10 to about 1.9 weight percent, in total, of a binary or ternary hindered amine light stabilizer combination selected from the group consisting of:
(2) bis(2,2,6,6-tetramethylpiperidin-4-yl) sebacate and (45) oligomeric compound condensate of 4,4?-hexamethylenebis(amino-2,2,6,6-tetramethylpiperidine) and 2,4-dichloro-6-[(2,2,6,6-tetramethylpiperidin-4-yl)butylamino]-s-triazine end-capped with 2-chloro-4,6-bis(dibutylamino)-s-triazine;
(20) 2,2,6,6-tetramethylpiperidin-4-yl octadecanoate and a (45) oligomeric condensate of 4,4?-hexamethylenebis(amino-2,2,6,6-tetramethylpiperidine) and 2,4-dichloro-6-[(2,2,6,6-tetramethylpiperidin-4-yl)butylamino]-s-triazine end-capped with 2-chloro-4,6-bis(dibutylamino)-s-triazine;
(2) bis(2,2,6,6-tetramethylpiperidin-4-yl) sebacate and (20) 2,2,6,6-tetramethylpiperidin-4-yl octadecanoate;
(2) bis(2,2,6,6-tetramethylpiperidin-4-yl) sebacate, (14) 1-(2-hydroxy-2-methyl-propoxy)-4-octadecanoyloxy-2,2,6,6-tetramethylpiperidine and a (45) oligomeric condensate of 4,4?-hexamethylenebis(amino-2,2,6,6-tetra-methylpiperidine) and 2,4-dichloro-6-[(2,2,6,6-tetramethylpiperidin-4-yl)butylaminol-s-triazine end-capped with 2-chloro-4,6-bis(dibutylamino)-s-triazine; and
(14) 1-(2-hydroxy-2-methylpropoxy)-4-octadecanoyloxy-2,2,6,6-tetramethylpiperidine, (20) 2,2,6,6-tetramethylpiperidin-4-yl octadecanoate and a (45) oligomeric condensate of 4,4?-hexamethylenebis(amino-2,2,6,6-tetramethylpiperidine) and 2,4-dichloro-6-[(2,2,6,6-tetramethylpiperidin-4-yl)butylamino-s-triazine end-capped with 2-chloro-4,6-bis(dibutylamino)-s-triazine;
one or more additional additives selected from:
one or more antioxidants,
one or more colorants,
one or more flame retardants, or
one or more antimicrobial compounds;
wherein:
any two of the binary or ternary HALS combinations have a weight ratio from about 1:5 to about 5:1;
the weight percents being based on the weight of the polyolefin substrate;
the extruded article is in the form of a house siding, cladding, soffit, or roofing, and has a thickness of about 0.030 inches to about 0.070 inches and a weight of from about 0.18 lbs/ft2 to about 0.31 lbs/ft2;
the polyolefin substrate comprises a nucleating agent and one or more fillers;
the nucleating agent comprises sodium benzoate, 2,2?-methylene-bis-(4,6-di-tert-butylphenyl)phosphate, zinc glycerolate, calcium salt of 1,2-dicarboxylic acid cyclohexane, aromatic trisamide compounds, cis-endo-bicyclo-[2.2.1]-heptane-2,3-dicarboxylic acid disodium salt, aluminum hydroxyl-bis[4-(tert-butyl)benzoate], 1,3:2,4-bis-(3,4-dimethylbenzylidene)sorbitol, 1,3:2,4-bis(4-methylbenzylidene)sorbitol, or 1,3:2,4-bis(3,4-dimethylbenzylidene)sorbitol; and
the extruded article exhibits impact strength of >35 in-lb measured according to ASTM D4226, coefficient of linear thermal expansion of <4.5×10E-05 in/in/ft measured according to ASTM D696, acceptable color uniformity in finished siding parts according to ASTM D6864, a low delta E color according to ASTM D2244 of ?5.0, and optionally a UL-94 V-1 or V-0 rating and/or a flame spread index of <200 measured according to ASTM E-84.
US Pat. No. 10,427,949

ALUMINA SINTERED BODY AND BASE SUBSTRATE FOR OPTICAL DEVICE

NGK Insulators, Ltd., Na...

1. An alumina sintered body having:a degree of c-plane orientation of 5% or more, which is determined by a Lotgering method using an X-ray diffraction profile in a range of 2?=20° to 70° obtained under X-ray irradiation, and an XRC half width of 15.0° or less in rocking curve measurement;
an F content of less than 0.99 mass ppm when measured by D-SIMS;
a crystal grain diameter of 15 to 200 ?m; and
25 or less pores having a diameter of 0.2 ?m to 1.0 ?m when a photograph of a viewing area 370.0 ?m in a vertical direction and 372.0 ?m in a horizontal direction taken at a magnification factor of 1000 is visually observed.
US Pat. No. 10,428,205

PNEUMATIC TIRE

1. A pneumatic tire having a tread comprising a radially outer cap layer and radially inner cap layer underlying the outer cap layer;the outer cap layer comprising a vulcanizable rubber composition comprising, based on 100 parts by weight of elastomer (phr),
(A) from about 80 to about 20 phr of a solution polymerized styrene-butadiene rubber having a glass transition temperature (Tg) ranging from ?85° C. to ?50° C.;
(B) from about 20 to about 80 phr of natural rubber; and
(C) from 30 to 70 phr of a process oil;
(D) from 70 to 150 phr of silica;wherein the weight ratio of silica to oil in the outer cap is less than 2.2;the inner cap layer comprising a vulcanizable rubber composition comprising:(i) from about 60 to about 40 phr of a solution polymerized styrene-butadiene rubber having a glass transition temperature (Tg) ranging from ?85° C. to ?50° C.;
(ii) from about 40 to about 60 phr of natural rubber;
(iii) from about 5 to 40 phr of a process oil;
(iv) from about 5 to 15 phr of a hydrocarbon traction resin; and
(v) from 60 to 90 phr of silica;wherein the weight ratio of silica to the sum of oil and traction resin is greater than 2.2.
US Pat. No. 10,426,158

POLYMERIC SORBENT FOR REMOVAL OF IMPURITIES FROM WHOLE BLOOD AND BLOOD PRODUCTS

CytoSorbents Corporation,...

1. A device comprising a plurality of porous sorbent polymeric beads for sorbing impurities from blood, said beads comprising a biocompatible polymer comprising particles having a diameter in the range for 0.1 micrometer to 2 centimeters and has a pore structure that the total pore volume of pore size in the range of 50 À to 40,000 À is greater than 0.5 cc/g to 5.0 cc/g dry polymer, and wherein (a) said plurality of beads being housed in a suitable container intended for storage of blood or blood product wherein said beads would be in direct contact with said blood or blood product or (b) said plurality of beads being contained in cartridge that is used (i) to filter the blood or blood product at time of collection as said or blood product is placed in a bag for storage or (ii) at the point of use during transfusion when said blood or blood product is transfused from the bag to a patient, andwherein said beads comprising divinylbenzene and 4-chlorostyrene and having a skeletal density in the range of from about 1.0 g/ml to about 1.3 g/ml.
US Pat. No. 10,427,183

DISCRETE MAGNETIC NANOPARTICLES

UNIVERSITY OF UTAH RESEAR...

1. A nanoparticle comprisinga magnetic core particle coated with at least one hydrophilic coating,
a plurality of layers coupled to the hydrophilic coating, wherein the plurality of layers comprises alternating layers of at least one polycationic layer and at least one polyanionic layer, and
a protective exterior coating,
wherein the magnetic particle has a diameter of at least 100 nm and exhibits a magnetic moment of at least about 1.5×10?13 emu.
US Pat. No. 10,428,207

RUBBER COMPOSITION

TOYO TIRE CORPORATION, I...

1. A rubber composition, comprising:a rubber component; and
a completely amorphous olefin based elastomer,
wherein the rubber component is a diene rubber,
wherein the completely amorphous olefin based elastomer has a glass transition temperature Tg of ?40 to 20° C. in an amount of 1 to 40 parts by mass when the entire amount of the rubber component is regarded as 100 parts by mass;
wherein the rubber composition includes terminal modified SBR in an amount of 5 to 80 parts by mass when the entire amount of the rubber component is regarded as 100 parts by mass.
US Pat. No. 10,426,160

COMPOSITIONS AND METHODS FOR PRESERVING RED BLOOD CELLS AND PLATELETS

RythRx Therapeutics, LLC,...

1. A composition comprising:a compound selected from the group consisting of:
((2R,3S,4R,5R)-5-(3-amino-5-methyl-1,4,5,6,8-pentaazaacenaphthylen-1(5H)-y)-3,4-dihydroxytetrahydrofuran-2-yl)methyl dihydrogen phosphate;
3-amino-5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-furan-2-yl)amino)-1-methylpyrimido[4,5-c]pyridazin-4(1H)-one; and
((2R,3S,4R,5R)-5-((3-amino-1-methyl-4-oxo-1,4-dihydropyrimido[4,5-c]pyridazin-5-yl)amino)-3,4-dihydroxytetrahydrofuran-2-yl)methyl dihydrogen phosphate; and
donated blood or a component thereof.
US Pat. No. 10,428,208

CROSS-LINKABLE NITRILE RUBBER COMPOSITION AND CROSS-LINKED RUBBER

ZEON CORPORATION, Tokyo ...

1. A cross-linkable nitrile rubber composition comprisinga highly saturated nitrile rubber (A) containing ?,?-ethylenically unsaturated nitrile monomer units in a ratio of from 10 to 60 wt % and having an iodine value of 120 or less,
a master batch (B) containing an ethylene-vinyl acetate copolymer (b1) having a melt flow rate measured under a load of 21.18N at 190° C. of from 0.5 to 1000 g/10 min. and containing vinyl acetate monomer units in a ratio of from 5 to 50 wt % and an organic staple fiber (b2) having an average fiber length of from 0.5 to 12 mm, and
a cross-linking agent (C),
wherein a ratio of a weight of the ethylene-vinyl acetate copolymer (b1) to a weight of the organic staple fiber (b2) in the master batch (B) is in a range of from 30:70 to 80:20.
US Pat. No. 10,428,465

HIGH STRENGTH AND LOW STIFFNESS AGAVE TISSUE

KIMBERLY-CLARK WORLDWIDE,...

18. A method of making a tissue web comprising the steps of:a. forming an aqueous suspension of high yield agave pulp fibers;
b. depositing an aqueous suspension of high yield agave pulp fibers onto a forming fabric;
c. dewatering the web to a consistency of about 20 percent or greater;
d. transferring the web to a throughdrying fabric
e. throughdrying the web, wherein the web comprises at least about 10 percent, by weight of the tissue web, high yield agave pulp fibers, and;
f. converting the web to a rolled tissue product, the product having a geometric mean tensile (GMT) from about 600 to about 1,200 g/3?, a Stiffness Index less than about 10.0 and a sheet bulk greater than about 10 cc/g.
US Pat. No. 10,428,210

POLYOLEFIN ADHESIVE COMPOSITIONS FOR ELASTIC APPLICATIONS

ExxonMobil Chemical Paten...

1. An article comprising a blend of(a) at least one propylene terpolymer comprising propylene derived units, one or more dienes, and one or more C2 or C4 to C20 alpha-olefins, where the C2 or C4 to C20 alpha-olefin content is less than about 35 wt % of the propylene terpolymer; and
(b) an adhesive composition, comprising
a polymer blend comprising a first propylene-based polymer, wherein the first propylene-based polymer is a homopolymer of propylene or a copolymer of propylene and ethylene or a C4 to C10 alpha-olefin, and a second propylene-based polymer, wherein the second propylene-based polymer is a homopolymer of propylene or a copolymer of propylene and ethylene or a C4 to C10 alpha-olefin; wherein the second propylene-based polymer is different than the first propylene-based polymer based on at least one property selected from the group consisting of comonomer content, heat of fusion, crystallinity, branching index, weight average molecular weight, and polydispersity, and wherein the polymer blend is present in the amount of about 20 to about 80 wt % of the adhesive composition.
US Pat. No. 10,426,163

BACTERICIDAL METHOD OF USING COMPOUNDS OF FATTY ACIDS AND AMMONIUM FATTY ACID SALTS

Falcon Lab, LLC, Wilming...

13. A method of disinfecting a bacterial contaminated surface comprising applying onto the surface a bactericidally effective amount of a solid compound of the structural formula (I):CH3(CH2)xCOOH.CH3(CH2)xCOO?NH4+  (I)wherein x is from 6 to 8.
US Pat. No. 10,427,187

MIXER SYSTEM FOR PRODUCING TOPCOAT COMPOSITIONS AND COATING COMPOSITIONS USED AS FILLER

BASF COATINGS GmbH, Muen...

1. A mixer system comprising a volumetric or gravimetric metering plant as a mixing apparatus and comprising at least the following components (a) to (d) and also optionally (e):(a) at least one pigment-free component (a) for producing at least one topcoat composition (A), with (a) comprising at least one binder (a1) and at least one organic solvent (a2) and optionally at least one matting agent (a3),
(b) at least one component (b), different from (a), for producing at least one coating composition (B) used as filling compound, where (b) comprises at least one binder (b1), at least one organic solvent (b2), and at least one filler (b3), where the binder (b1) comprises at least one unsaturated polyester and/or at least one polyurethane,
(c) a plurality of different pigment pastes different from the components (a), (b), (d), and optionally (e), which in each case independently of one another comprise at least one binder (c1), at least one organic solvent (c2), and at least one pigment (c3),
(d) a plurality of different, binder-free dye solutions, which each independently of one another comprise at least one organic solvent (d1) and at least one dye (d2), and
(e) optionally one or more different organic solvents, which may optionally comprise at least one additive and/or at least one crosslinking agent.
US Pat. No. 10,428,211

FLUOROPOLYMER COMPOSITION FOR MOBILE ELECTRONIC DEVICE

SOLVAY SPECIALTY POLYMERS...

1. A fluoropolymer composition (C), said composition (C) comprising:at least one vinylidene fluoride (VDF) homopolymer [PVDF] in an amount of from 55 to 85% wt, said PVDF possessing a first molecular weight (MPVDF);
at least one VDF semi-crystalline copolymer comprising recurring units derived from VDF and recurring units derived from HFP [VDF copolymer] in an amount of from 15 to 45% wt, said VDF copolymer possessing a second molecular weight (MVDF copolymer) such that MVDF copolymer is higher than MPVDF;
the % wt being with respect to the sum of weights of PVDF and VDF copolymer, and
at least one high density ethylene polymer (PE), comprising more than 70% weight of recurring units derived from ethylene, and optionally comprising recurring units derived from at least one alpha-olefin different from ethylene, said polymer (PE) possessing a density of from 930 to 970 kg/m3, said polymer (PE) being comprised in an amount of at least 0.05 weight parts and at most 5 weight parts, per 100 weight parts of combined amount of PVDF and VDF copolymer.
US Pat. No. 10,426,164

METHODS AND COMPOSITIONS FOR CLEANING AND DISINFECTING SURFACES

Maria Beug-Deeb, inc., R...

1. A method of reducing bacteria in a biofilm on a biofilm-containing environmental surface;wherein
the environmental surface is a washable, nonporous surface;
the method comprising contacting the environmental surface with an aqueous composition comprising
an organic surfactant derived from the saponification of one or more natural oils consisting essentially of
at least 1-6% caproic, caprylic and capric acid salts, and at least 30% lauric and myristic acid salts; and
wherein the organic surfactant and citric acid are each present in sufficient amounts to achieve at least a 3 log reduction (99.9%) of bacteria on the biofilm-containing environmental surface within two minutes or less.
US Pat. No. 10,428,213

(METH)ACRYLIC RESIN COMPOSITION AND RESIN MOLDED ARTICLE

Mitsubishi Chemical Corpo...

1. A (meth)acrylic resin composition comprising a (meth)acrylic polymer (P) and a phosphorus atom-containing compound (C), whereinthe (meth)acrylic polymer (P) comprises
(1) a repeating unit derived from methyl methacrylate at 19.95% by mass or more and 84.95% by mass or less,
(2) repeating units derived from a (meth)acrylic acid ester (M), including
(2-1) a repeating unit derived from a methacrylic acid ester (M1) having an aromatic hydrocarbon group or an alicyclic hydrocarbon group having from 3 to 20 carbon atoms in a side chain at 10% by mass or more and 79.5% by mass or less and
(2-2) a repeating unit derived from an acrylic acid ester (M2) having an aromatic hydrocarbon group or an alicyclic hydrocarbon group having from 3 to 20 carbon atoms in a side chain at 0.50% by mass or more and 20% by mass or less, and
(3) a repeating unit derived from a monomer (B) having two or more vinyl groups at 0.05% by mass or more and 0.40% by mass or less;
a sum of the repeating unit derived from a methacrylic acid ester (M1) and the repeating unit derived from an acrylic acid ester (M2) is 15.0% by mass or more and 80.0% by mass or less; and
an amount of the phosphorus atom-containing compound (C) with respect to 100 parts by mass of the (meth)acrylic polymer (P) is 5.0 parts by mass or more and 35 parts by mass or less.
US Pat. No. 10,428,214

CATIONICALLY CURABLE RESIN COMPOSITION

THREEBOND CO., LTD., Tok...

1. A cationically curable resin composition comprising:component (A): a cationically polymerizable compound;
component (B): a photo-cationic polymerization initiator;
component (C): a thermal cationic polymerization initiator; and
component (D): a compound having an isocyanuric ring,
wherein a content of the component (D) is 0.01 to 5 parts by mass per 100 parts by mass of the component (A).
US Pat. No. 10,428,216

GOLF BALL INCORPORATING A MIXTURE OF A THERMOSET AND/OR THERMOPLASTIC COMPOSITION AND A PLURALITY OF CONDUCTIVE NANOSHELLED STRUCTURES

Acushnet Company, Fairha...

1. A golf ball having a CoR of at least 0.700 and a compression of at least 50 and comprising at least one layer consisting of a mixture of thermoset or thermoplastic composition and a plurality of conductive nanoshelled structures that are hexagon-shaped.
US Pat. No. 10,429,755

WHITE TONER FOR ELECTROSTATIC IMAGE DEVELOPMENT, ELECTROSTATIC IMAGE DEVELOPER, TONER CARTRIDGE, PROCESS CARTRIDGE, IMAGE FORMING APPARATUS, AND IMAGE FORMING METHOD

FUJI XEROX CO., LTD., To...

1. A white toner for electrostatic image development, the toner comprising:white toner particles containing a binder resin and a white pigment,
wherein when in a circularity distribution of the white pigment determined by sectional observation of the white toner particles, the cumulative 10% circularity from the smaller side is C10, and the cumulative 50% circularity is C50, the following formula (1) and formula (2) are satisfied,
0.900?C50?1.000  Formula (1):
1.00?C50/C10?1.13.  Formula (2):
US Pat. No. 10,428,217

LIQUID POTHOLE FILLER COMPOSITION AND METHOD

1. A pothole filler system of liquid and solid components for mixing in situ and poured as a liquid into a pothole, comprising: an anionic aqueous asphalt and chloroprene emulsion liquid component in a volume ratio of from about 60:40 to about 70:30 and having a pH of from about 12 to 12.9, which is shelf stable for months; a solid component comprising crumb rubber mixed with calcined clay in a weight ratio of crumb rubber to calcined clay is from about 3:1 to about 1:1; and a catalytic quantity of a hydrous calcium sulfate activator, which may be an ingredient of the solid component or can be added at the time of in situ mixing, wherein when mixed in situ, the resulting in situ mixture remains stable through hardening, and can be poured into the pothole as a liquid mixture which hardens in 60 minutes or less and can be driven on immediately upon hardening.
US Pat. No. 10,431,804

SECONDARY BATTERY AND SECONDARY BATTERY ASSEMBLY

SANYO Electric Co., Ltd.,...

1. A secondary battery comprising:an electrode assembly including a first electrode and a second electrode;
an outer body having an opening and housing the electrode assembly;
a sealing plate sealing the opening and made of a conductive material;
a deformable member that is deformed when the pressure inside the outer body becomes equal to or higher than a predetermined value; and
a conductive second electrode connecting member electrically connected to the second electrode,
wherein the sealing plate has a first through-hole,
wherein the deformable member hermetically seals the first through-hole,
wherein the second electrode connecting member is disposed on the outer side of the deformable member,
wherein a conductive conducting member is disposed between the second electrode connecting member and the deformable member,
wherein the outer diameter of the conducting member is larger than the inner diameter of the first through-hole,
wherein when the pressure inside the outer body becomes equal to or higher than the predetermined value, the deformable member is deformed and thereby brings the conducting member into contact with the second electrode connecting member and electrically connects the first electrode and the second electrode, and
wherein an insulating member is disposed between the second electrode connecting member and the conducting member,
wherein the insulating member has a second through-hole, and
wherein the conducting member has a protruding portion that protrudes toward the second electrode connecting member into the second through-hole.
US Pat. No. 10,426,170

COMPOSITIONS AND METHODS FOR REDUCING INFESTATION OF WEEDS OR UNWANTED PLANTS WHILE MINIMIZING INJURY OR DAMAGE TO PLANTS OR CROPS

BAYER CROPSCIENCE LP, St...

1. A method for controlling, mitigating, or reducing weed infestation and/or damage in a glyphosate tolerant or resistant seed, plant, or crop, comprising treating soil, a plant, and/or a plant part with as the sole herbicides:a) a HPPD inhibitor herbicide;
b) glyphosate; and
c) fomesafen,wherein said HPPD inhibitor herbicide is selected from the group consisting of mesotrione, tembotrione, isoxaflutole, and bicyclopyrone and wherein the presence of fomesafen with said a and b increases crop yield and lowers the phytotoxicity relative to said a and b combined.
US Pat. No. 10,426,171

METHODS FOR PROPHYLAXIS OF INFECTIONS IN CROPS AND ORNAMENTALS, PREFERABLY IN VITICULTURE, AND IN WOODY PLANTS

BIOPRACT GMBH, Berlin (D...

1. A method for prophylaxis of infection by Plasmopara viticola in crops and ornamental plants, comprising spraying plants with an aqueous solution of a bacterial serine protease, characterized in that said bacterial serine protease is derived from Bacillus sp. or Nocardiopsis sp.
US Pat. No. 10,427,195

CHEMICAL OXIDATION METHOD AND COMPOUNDS

OXYTEC LLC, Newton, MA (...

1. A method of reducing the concentration of perfluoroalkyl compounds in a contaminated material, the method comprising:desorbing at least one of the perfluoroalkyl compounds from the contaminated material;
forming a soluble cyclic oligosaccharide/perfluoroalkyl complex with the at least one perfluoroalkyl compound in an aqueous phase; and
destroying the cyclic oligosaccharide/perfluoroalkyl complex in the aqueous phase, wherein a concentration of the at least one perfluoroalkyl compound in the contaminated material is reduced by greater than 50% of an original concentration, and the concentration of the at least one perfluoroalkyl compound is reduced to less than 1.0 ppm in the contaminated material, wherein the contaminated material comprises at least one of soil, sediment and rock.
US Pat. No. 10,428,223

PRETREATMENT HAVING IMPROVED STORAGE STABILITY AND ADHESION

SIKA TECHNOLOGY AG, Baar...

1. A composition consisting essentially of:A) at least one aminosilane which has at least one hydrolyzable group bonded to Si,
B) at least one mercaptosilane which has at least one hydrolyzable group bonded to Si,
C) at least one emulsifier selected from propionamides and amino alcohol reaction products,
wherein, if the at least one emulsifier is an amino alcohol reaction product, the amino alcohol reaction product is a reaction product of an amino alcohol and at least part of the aminosilane and/or mercaptosilane, and in the amino alcohol reaction product, at least some of the hydrolyzable groups present in the at least one aminosilane and the at least one mercaptosilane are replaced by an amino alcoholate group present in the amino alcohol,
D) hydrolysis and/or condensation products of the at least one aminosilane and the at least one mercaptosilane,
E) water,
F) at least one acid, and
G) at least one surfactant.
US Pat. No. 10,428,224

LOW GLOSS POWDER COATING

TIGER DRYLAC U.S.A. INC.,...

1. A curable powder coating composition comprising one or more cross-linkable fluoro containing organic oligomer(s) and/or polymer(s) (A), one or more crosslinker(s) (B) able to react with (A), one or more compound(s) (C) able to react with (A) and/or (B), and melamine and/or a melamine derivative; wherein the one or more crosslinker(s) is distinct from the melamine and the melamine derivative.
US Pat. No. 10,428,225

LOW REFLECTANCE POWDER COATING COMPOSITION

SWIMC LLC, Cleveland, OH...

1. A powder coating composition comprising:(a) a first hydroxyl functional acrylic powder resin having a hydroxyl value of at least about 180 and having a Tg of at least 35° C.;
(b) a second hydroxyl functional acrylic powder resin having a hydroxyl value between about 45 and about 80 and having a Tg of at least 35° C.;
(c) a blocked isocyanate crosslinker reactive with the first hydroxyl functional acrylic powder resin and the second hydroxyl functional acrylic resin; and
(d) wollastonite;and wherein the weight ratio of the first acrylic powder resin to the second acrylic powder resin is at least about 0.5, the first acrylic powder resin is present at a level to provide between about 33.3 weight percent and 85.1 weight percent of the total combined weight of the first acrylic powder resin and the second acrylic powder resin, the blocked isocyanate crosslinker is present at a level about 1.0 to about 1.5 equivalents of isocyanate functionality for each equivalent of active hydrogen of the first and second hydroxyl functional acrylic resins, the wollastonite is present at a level of at least 10% to about 25% by weight of the coating composition, and the coating composition when applied to a substrate and cured will have a 60° gloss less than 1 and an 85° gloss 3.5 or less.
US Pat. No. 10,428,226

SOL-GEL COATING COMPOSITIONS AND RELATED PROCESSES

The Boeing Company, Chic...

17. A corrosion-resistant coated product, comprising:a plurality of ultraviolet (UV)-cured sol-gel layers on a substrate, each of the UV-cured sol-gel layers comprising a photoinitiator and a polymer composite of a methacryloxyalkyl alkoxysilane, an aryl alkoxysilane, an aminoalkyl alkoxysilane, a glycidoxyalkyl alkoxysilane, a zirconium alkoxide, and an organic acid, and each of the UV-cured sol-gel layers having a ratio of a number of moles of silicon to a number of moles of zirconium (nSi/nZr) ranging from about 2 to about 10.
US Pat. No. 10,427,972

TRANSPARENT SILICATE GLASSES WITH HIGH FRACTURE TOUGHNESS

CORNING INCORPORATED, Co...

1. A glass based article comprising:SiO2 in the range of 35 mol % to 80 mol %;
Al2O3 in the range of 1 mol % to 15 mol %;
alkali metals in the range of 0 mol % to 5 mol % of total alkali metals, collectively; and
two or more metal oxides selected from the group consisting of La2O3, BaO, Ta2O5, Y2O3, and HfO2, wherein the combined molar percentages of the two or more metal oxides are at least 15 mol %, and
wherein the glass based article has a fracture toughness of at least 0.86 MPa*m0.5.
US Pat. No. 10,428,228

PRE-TREATMENT AND CLEANING OF EQUIPMENT USED WITH UNCURED CEMENTITIOUS MATERIALS

Arris Technologies, LLC, ...

1. A system for treating equipment for mixing, placing or finishing a cementitious material, comprising:a composition comprising a colloidal silica, the composition formulated to enable the colloidal silica to prevent cementitious material from adhering to a surface of the equipment and/or to enable the colloidal silica to soften hardened and/or cured cementitious material to facilitate removal of the hardened and/or cured cementitious material from the surface of the equipment; and
abrasive particles capable of use with the composition.
US Pat. No. 10,426,181

METHOD FOR PREPARING HIGH ACID RTD WHOLE GRAIN BEVERAGES

The Quaker Oats Company, ...

1. A method for preparing a low viscosity whole grain flour slurry comprising the following steps to be performed in the order listed:a) dispersing whole grain flour in water at a ratio of 1:8 to 1:20 at a temperature of 87 to 99° C. to obtain a flour-water mixture;
b) reducing the temperature of the flour-water mixture to 49-71° C.;
c) adding alpha-amylase to reduce the viscosity of the flour-water mixture to 40 to 60 cp when measured at about 70° C., wherein alpha-amylase is the only enzyme added to the mixture; and
d) acidifying the flour-water mixture to reduce the pH of the flour-water mixture to less than 5 and to obtain a low viscosity whole grain flour slurry wherein about 50 percent of the flour contained in the slurry has an average particle size of less than 91 microns.
US Pat. No. 10,427,973

PYROLYTIC HYBRID ENAMEL

Ferro Corporation, Mayfi...

1. A composition for forming an enamel cover coat, the composition comprising at least a first glass frit comprising by weight:from about 6.3% to about 7.4% Na2O;
from about 6.3% to about 7.4% K2O;
from about 9.9% to about 11.9% SiO2;
from about 25.7% to about 29.7% P2O5;
from about 12.7% to about 14.7% ZrO2;
from about 16.8% to about 20.8% Al2O3;
from about 0.6% to about 4.0% TiO2;
from about 0.1% to about 2.0% Li2O;
from about 0.1% to about 2.0% BaO;
from about 0.1% to about 5.0% Co2O3;
from about 0.1% to about 1.0% Cr2O3;
from about 10.3% to about 14.3% B2O3; and
from about 0.1% to about 3.0% F.
US Pat. No. 10,426,182

METHOD FOR PRESERVING FOOD

NECST S.R.L., Padua (IT)...

1. A method for preserving organoleptic characteristics associated with a cooked food, comprising the steps of:placing the cooked food having organoleptic characteristics of: taste, odor, appearance and texture in an atmospheric preservation chamber;
establishing and maintaining a temperature in the atmospheric preservation chamber in a range between 58° C. to 72° C.;
introducing a non-oxidizing gas into the atmospheric preserving chamber;
establishing and maintaining an oxygen pressure in the atmospheric preserving chamber below 10 kPa; and,
maintaining the temperature, pressure, and organoleptic characteristics of: taste, odor, appearance and texture until the cooked food product is removed from the preserving chamber no sooner than 24 hours from the time the cooked food is placed in the atmospheric preserving chamber.
US Pat. No. 10,426,950

METHODS AND DEVICES FOR TREATING PARASYMPATHETIC BIAS MEDIATED CONDITIONS

Palo Alto Investors, Pal...

1. A method of treating a subject, the method comprising:testing a subject that has not been previously diagnosed with a food allergy and has ingested a nutritional composition known to have a high incidence of allergic reaction to determine that the subject has parasympathetic bias and vagal bias by measuring one or more aspects of the subject's autonomic nervous system selected from the group consisting of: an amount of T helper cells, a conduction, a catecholamine level, heart rate variability, a hormone level, a chronotropic vasodilator response and an inotropic vasodilator response, to detect the parasympathetic bias and vagal bias; and
modulating at least a portion of the tested subject's autonomic nervous system via an electrical protocol comprising applying an electrical stimulation to at least one nerve fiber of the subject via a device to increase the sympathetic/parasympathetic activity ratio in a manner effective to treat the subject for the food allergy.
US Pat. No. 10,428,231

GEL PARTICLES, INK COMPOSITION AND PRODUCTION METHOD THEREOF, PHOTOSENSITIVE COMPOSITION, AND IMAGE FORMING METHOD

FUJIFILM CORPORATION, To...

1. An ink composition for ink jet comprising:gel particles which have a polymerizable group, and a three-dimensional crosslinked structure including at least one bond selected from a urethane bond and a urea bond, and enclose a photopolymerization initiator; and
water.
US Pat. No. 10,426,184

SEAWEED MEAL AND METHOD OF MAKING THE SAME

NUTRIOMIX, INC., Pasaden...

1. A method of preparing a high quality seaweed meal suitable for food applications, consisting of:cleaning seaweed material with water, wherein the seaweed material is dry, fresh, or rehydrated seaweed material;
pre-treating the seaweed with an alkali;
pre-treating the seaweed with an acid; and
treating the pre-treated seaweed with a cellulase, thereby to obtain the seaweed meal.
US Pat. No. 10,427,979

GYPSUM PANELS, METHODS, AND SYSTEMS

Georgia-Pacific Gypsum LL...

1. A method of making a gypsum panel, comprising:combining gypsum stucco and a halide salt sequestration agent with water to form a gypsum slurry; and
setting the gypsum slurry to form at least a portion of a gypsum core,
wherein the halide salt sequestration agent is present in an amount effective to sequester at least 25 percent, by weight, of halide salt present in the gypsum stucco.
US Pat. No. 10,427,212

COMPOSITIONS AND METHODS FOR MODIFIED ESTER-CURATIVES AND REDUCTION OF FORMALDEHYDE EMISSION AND ODOR IN ESTER-CURED PHENOLIC BINDER SYSTEMS

HA-International, LLC, W...

1. A method for reducing formaldehyde emissions from ester-cured foundry binders used in the formation of foundry molds and cores, the method comprising the steps of:(a) combining an aggregate with a water soluble alkaline phenolic resole resin to form a first admixture;
(b) combining an ester-curative with resorcinol to form a modified ester-curative; and
(c) combining the first admixture with the modified ester-curative to form a second admixture;
wherein the modified ester-curative is configured to affect a reduced emission of formaldehyde from the second admixture.
US Pat. No. 10,428,236

POLYURETHANE UREA RESIN COMPOSITION EXHIBITING UV-ABSORPTION-AGENT RESISTANCE, MOULDED BODY USING SAID COMPOSITION, AND COATING MATERIAL

TOSOH CORPORATION, Shuna...

1. A polyurethane urea resin composition having UV-absorption-agent resistance, comprising:an organic solvent; and
a polyurethane urea resin dissolved in the organic solvent and comprising a monomer unit derived from a polyol, a monomer unit derived from a polyisocyanate, a monomer unit derived from a molecular weight modifier, and a monomer unit derived from a diamine, and the polyurethane urea resin has a urea group concentration in a range of 0.5 to 1 mmol/g, a urethane group concentration of 1 mmol/g or less, and a urethane group concentration ratio in a range of 40 to 59% where the urethane group concentration ratio=the urethane group concentration×100/(the urethane group concentration+the urea group concentration).
US Pat. No. 10,428,237

AQUEOUS COATING COMPOSITION WITH SOFT TOUCH UPON DRYING

DSM IP ASSETS B.V., Heer...

1. An aqueous coating composition comprising dispersed polymer particles,wherein
(i) the dispersed polymer particles are polyurethane-vinyl polymer hybrid particles obtained by free-radical polymerization of at least one vinyl monomer in the presence of a polyurethane,
(ii) the polyurethane and the vinyl polymer in the hybrid particles are present in a weight ratio of polyurethane to vinyl polymer from 1:1 to 20:1,
(iii) the polyurethane is the reaction product of at least the following components:
(a) from 5 to 40 wt. % of at least one organic difunctional isocyanate,
(b) from 0.5 to 4 wt. % of an isocyanate-reactive compound containing ionic or potentially ionic water-dispersing groups having a molecular weight of from 100 to 500 g/mol,
(c) from 40 to 80 wt. % of at least one diol having a molecular weight from 500 to 5000,
(d) from 0 to 10 wt. % of at least one active-hydrogen chain extending compound other than water with a functionality of at least 2, and
(e) from 0 to 10 wt. % of at least one diol having a molecular weight below 500 g/mol, wherein
the amounts of components (a), (b), (c), (d) and (e) are relative to the total amount of components used to prepare the polyurethane from which the building blocks from the polyurethane are emanated, and wherein
the isocyanate and hydroxy groups on the components used to prepare the polyurethane are present in a respective mole ratio (NCO to OH) in the range of from 0.8:1 to 5:1.
US Pat. No. 10,427,215

PUNCH UNIT AND POWDER PRESS MOLDING DEVICE FOR MANUFACTURING COMPACTED POWDER PELLET

DENSO CORPORATION, Kariy...

1. A punch unit used in a powder press molding device that includes a die plate including a cavity in which a compacted powder pellet can be formed, the powder press molding device including a ram moving in a direction approaching the die plate and in a direction away from the die plate, the punch unit comprising:a punch inserted into the cavity of the die plate when the ram approaches the die plate; and
a supporting portion supporting the punch reciprocatably in a moving direction of the ram, the punch unit being movable along a plane intersecting with the moving direction of the ram in a state where the punch is removed from the cavity.
US Pat. No. 10,427,987

ORGANIC FERTILIZER FOR VEGETABLES AND ITS PREPARATION METHOD

1. A method of preparation of an organic fertilizer for vegetables comprising:picking mature okra fruits then washing and sterilizing the okra fruits;
anaerobic depositing of the sterilized okra fruits for 3 to 5 days at a temperature range of 18 to 25 degree C. to obtain a matrix of the organic fertilizer for vegetables;
adding 1 part of a colloidal fluid of Bacillus to 0.95 to 0.98 part of the matrix of the organic fertilizer for vegetables to obtain a second fluid of the organic fertilizer for vegetables by an anaerobic fermentation for 30-60 days under hermetic closure, shading and sterilization at temperature 20 to 35 degree C.; and
adding 5 to 10 fractions of the second fluid of the organic fertilizer for vegetables to a mixture of 10 to 15 fractions of chicken droppings, 20 to 25 fractions of soybean crop waste, 10 to 15 fractions of plant ashes and 45 to 60 fractions of water followed by standing for 30 to 60 days at temperature of 20 to 35 degree C. to obtain the organic fertilizer for vegetables.
US Pat. No. 10,427,989

ANTI-FUNGAL SEED TREATMENT FORMULATIONS, TREATED SEEDS, AND METHODS

Germain Seed Technology, ...

1. A coated seed comprising:a seed and
a coating at least partially surrounding the seed,
wherein the coating comprises a fungicide, a micronutrient metal, and a chelating agent, the fungicide comprising copper (II) hydroxide, wherein the amount of copper (II) hydroxide is from about 0.12 mg/ seed to about 0.21 mg/ seed.
US Pat. No. 10,427,992

ETHANE OXIDATIVE DEHYDROGENATION AND ACETIC ACID RECOVERY

SHELL OIL COMPANY, Houst...

1. A process for oxidative dehydrogenation of ethane, comprising the steps of:(a) feeding a gas stream comprising ethane and propane to a distillation column to obtain a stream comprising propane and a stream comprising ethane;
(b) feeding at least a part of the gas stream comprising ethane obtained in step (a) to a reactor;
(c) contacting, in the reactor, oxygen and ethane and optionally ethylene with a catalyst comprising a mixed metal oxide;
(d) cooling the reactor effluent and, simultaneously and/or in a subsequent step, add water to the reactor effluent to obtain a liquid stream comprising water and acetic acid and a gas stream comprising ethylene;
(e) recovering the acetic acid from the liquid stream obtained in step (d) by means of solvent extraction;
wherein at least 50 wt % of the mixed metal oxide in the catalyst used in step (c) is in the orthorhombic M1 crystalline phase; and
wherein the mixed metal oxide in the catalyst used in step (c) comprises:
molybdenum, vanadium and antimony, or
molybdenum, vanadium, niobium and optionally tellurium or antimony.
US Pat. No. 10,428,248

COMPOSITIONS, MATERIALS, AND METHODS FOR ENHANCING 3D PRINTER PLATFORM ADHESION AND/OR REDUCING WARPAGE IN PRINTED PARTS

1. A composition for promoting adhesion between a 3D printed material and a print platform comprising:0. 05-7 wt. % urea;
1-15 wt. % gelatin;
1-8 wt. % acetic acid;
58-99 wt. % water; and
0.1-5 wt. % polyvinylpyrrolidone, wherein the weight percentage is with respect to the total weight of the composition.
US Pat. No. 10,426,714

SPRAYABLE SUNSCREEN COSMETIC

SHISEIDO COMPANY, LTD., ...

1. A water-in-oil emulsified sunscreen cosmetic, comprising:(A) 6 to 40 mass % of an ultraviolet ray absorbing agent;
(B) an organically modified clay mineral;
(C) an oil phase thickener selected from the group consisting of dextrin fatty acid esters, sucrose fatty acid esters, and fatty acids solid at ambient temperature and salts thereof;
(D) a silicone-based surfactant having an HLB of less than 8;
(E) a spherical resin powder;
(F) a volatile silicone oil; and
(G) one or more non-volatile liquid oils other than silicone oils;
wherein a ratio of [total amount of ingredient (B)+ingredient (C)]/[a total amount of (G) non-volatile liquid oils other than silicone oils] is at least 0.04 and less than 0.68.
US Pat. No. 10,427,994

SEPARATION PROCESS FOR C8 AROMATICS MIXTURE

SCG CHEMICALS CO., LTD., ...

1. A process for the distillative separation of ethylbenzene from a mixture comprising ethylbenzene and at least one other C8 aromatic compound, the process comprising:adding at least one solvent to a distillation column, the at least one solvent including one or more of chloroform, carbon tetrachloride, dimethylamine, diethylamine, acetonitrile, acetaldehyde, 1-propanal, methyl isopropyl ketone, 3-methyl-2-pentanone, 3,3-dimethyl-2-butanone, 2-pentanone, 2-methylpropanal, 1-butanal, cyclopentanone, acetone, or ethanol;
adding one or more of water or steam to the distillation column; and
distilling said mixture in the distillation column in the presence of an extractive solvent, the at least one solvent, the one or more of water or steam, and at a sub-atmospheric pressure.
US Pat. No. 10,428,250

METHOD FOR PRODUCING TEXTILE PRODUCTS, PRODUCTS OBTAINABLE THEREFROM AND METHOD TO RECLAIM THE PRODUCTS

DSM IP ASSETS B.V, Heerl...

1. A hot melt adhesive comprising a polymer P in an amount of at least 50% by weight of the hot melt adhesive composition, whereinthe polymer P is a polyester which is a condensation polymerization reaction product of a dicarboxylic acid and a polyol having two hydroxyl groups per molecule, and wherein
the polymer P is semi-crystalline and has a melting point from 75 to 150° C., a glass transition temperature below 40° C. and a melt viscosity at 150° C. of lower than 100 Pa·s and higher than 8 Pa·s, wherein
the hot melt adhesive is thermoplastic.
US Pat. No. 10,426,715

LIPOSOME COMPOSITION

KOSE CORPORATION, Tokyo ...

1. A liposome comprising the following ingredients (a) to (e):(a) A phospholipid
(b) A Tremella fuciformis extract
(c) Vitamin E or a derivative thereof
(d) A polyhydric alcohol having an IOB value of 1.5 to 5
(e) Water,
wherein the ingredient (d) consists of one or more selected from the group consisting of 1,3-butylene glycol, glycerin, and dipropylene glycol, and
wherein content of the ingredient (d) contained in the liposome is in the range of 10 to 25%.
US Pat. No. 10,431,326

METHOD FOR INDICATING A PRESENCE OR NON-PRESENCE OF AGGRESSIVE PROSTATE CANCER

PHADIA AB, Uppsala (SE)

1. A method for determining aggressive prostate cancer (PCa) markers in an individual, comprising the steps of:(i) Providing at least one biological sample from said individual;
(ii) Contacting the biological sample with an assay device comprising a first category of ligands which bind specifically to at least three kallikrein family protein PCa biomarkers, the first category of ligands including a plurality of different ligands binding specifically to each of the at least three kallikrein family protein PCa biomarkers, wherein the at least three PCa biomarkers include at least one of PSA, intact PSA (iPSA), total PSA (tPSA), free PSA (fPSA), and hK2;
(iii) Contacting the biological sample with an assay device comprising a solid phase having immobilised thereon a second category of ligands which bind specifically to at least 80 SNPs related to PCa (SNPpc), the second category of ligands including a plurality of different ligands binding specifically to each of said SNPpc, wherein
(a) said at least 80 SNPpc are selected from the group consisting of rs582598, rs439378, rs2207790, rs1046011, rs10458360, rs7525167, rs10489871, rs7529518, rs4245739, rs4512641, rs10178804, rs11900952, rs1873555, rs10191478, rs6755901, rs6545962, rs721048, rs2710647, rs12612891, rs2028900, rs1009, rs12233245, rs6760417, rs10496470, rs10199796, rs12475433, rs16860513, rs12151618, rs3765065, rs13017302, rs12988652, rs871688, rs749264, rs3771570, rs4346531, rs6770955, rs12637074, rs2660753, rs13319878, rs6437715, rs2162185, rs1515542, rs2270785, rs9830294, rs1439024, rs6762443, rs888507, rs6794467, rs12490248, rs1477886, rs4833103, rs3796547, rs17779822, rs2366711, rs16849146, rs1894292, rs12640320, rs3805284, rs12500426, rs4699312, rs17021918, rs7679673, rs2047408, rs2647262, rs12506850, rs7658048, rs2078277, rs12505546, rs13113975, rs4246742, rs2736098, rs401681, rs11134144, rs10060513, rs40485, rs2087724, rs1482679, rs16901841, rs1295683, rs2070874, rs7752029, rs2018334, rs9358913, rs1140809, rs409558, rs3096702, rs9267911, rs2025645, rs9359428, rs6569371, rs2813532, rs1933488, rs712242, rs6934898, rs9456490, rs651164, rs3120137, rs9364554, rs9457937, rs10486562, rs10807843, rs7801918, rs6962297, rs2465796, rs6957416, rs7777631, rs2272316, rs6961773, rs2132276, rs13265330, rs16887736, rs2911756, rs2272668, rs2339654, rs1380862, rs9297746, rs12543663, rs10086908, rs16901922, rs1016343, rs17832285, rs16901979, rs4871779, rs10107982, rs16902094, rs620861, rs17467139, rs6983267, rs9297756, rs10094059, rs7818556, rs1992833, rs986472, rs12552397, rs4273907, rs4237185, rs753032, rs11253002, rs2386841, rs10795841, rs10508422, rs7075945, rs10508678, rs539357, rs10826398, rs3818714, rs7090755, rs10993994, rs4382847, rs1891158, rs10887926, rs10788160, rs6579002, rs10832514, rs7358335, rs1944047, rs3019779, rs10896437, rs12793759, rs7106762, rs7102758, rs2449600, rs585197, rs2509867, rs11568818, rs7125415, rs11601037, rs11222496, rs4570588, rs6489721, rs3213764, rs17395631, rs4423250, rs11168936, rs10875943, rs3759129, rs902774, rs1827611, rs4760442, rs11610799, rs6539333, rs11067228, rs7485441, rs6489794, rs4119478, rs17070292, rs2293710, rs17256058, rs1950198, rs2331780, rs7141529, rs12880777, rs17123359, rs785437, rs524908, rs12903579, rs7178085, rs7164364, rs896615, rs11634741, rs9972541, rs12594014, rs11631109, rs1558902, rs8044335, rs2738571, rs885479, rs385894, rs684232, rs4925094, rs17138478, rs11649743, rs2107131, rs7213769, rs12946864, rs306801, rs138213197, rs1863610, rs17224342, rs9911515, rs12947919, rs966304, rs17744022, rs7234917, rs1943821, rs2227270, rs1363120, rs888663, rs1227732, rs1054564, rs4806120, rs11672691, rs758643, rs3745233, rs6509345, rs2659051, rs2735839, rs1354774, rs2691274, rs6090461, rs2297434, rs6062509, rs2315654, rs2823118, rs2838053, rs398146, rs16988279, rs2269640, rs4822763, rs132774, rs747745, rs5978944, rs6530238, rs5934705, rs5935063, rs4830488, rs17318620, rs5945619, rs5945637, rs11091768, rs2473057, rs5918762, rs4844228, rs6625760 and rs17324573; or
(b) wherein said at least 80 SNPpc are selected from the group consisting of 657del5, rs10086908, rs1016343, rs10187424, rs1041449, rs10486567, rs1054564, rs10875943, rs10896449, rs10934853, rs10993994, rs11067228, rs11135910, rs11228565, rs11568818, rs11649743, rs11650494, rs11672691, rs11704416, rs12130132, rs12409639, rs12418451, rs12500426, rs12543663, rs12621278, rs12653946, rs1270884, rs130067, rs13252298, rs13385191, rs1354774, rs1363120, rs137853007, rs138213197, rs1447295, rs1465618, rs1512268, rs1571801, rs16901979, rs16902094, rs17021918, rs17632542, rs17879961, rs1859962, rs1894292, rs1933488, rs1983891, rs2018334, rs2121875, rs2242652, rs2273669, rs2292884, rs2405942, rs2660753, rs2735839, rs2736098, rs2928679, rs3213764, rs339331, rs3771570, rs3850699, rs3863641, rs401681, rs4245739, rs4430796, rs445114, rs4643253, rs4857841, rs4962416, rs5759167, rs5919432, rs5945619, rs6062509, rs620861, rs6465657, rs6763931, rs684232, rs6869841, rs6983267, rs6983561, rs7127900, rs7210100, rs721048, rs7241993, rs7611694, rs7679673, rs7931342, rs8008270, rs8102476, rs888663, rs902774, rs9364554, rs9600079, and rs9623117;
(iv) Measuring
a. a presence or concentration of each of said PCa biomarkers binding the ligands in said first category; and
b. a presence or absence of each of said SNPpc binding the ligands in said second category;
(v) Combining measurement data of the at least three PCa biomarkers binding ligands from said first category from step (iv)a according to a first predetermined equation to form a biomarker composite value, wherein the combination according to the first predetermined equation allows omission of measurement data of a subset of said PCa biomarkers when forming said biomarker composite value, wherein the subset comprises at least one, but not all, of said three kallikrein family protein PCa biomarkers;
(vi) Combining measurement data of the at least 80 SNPpc binding ligands from said second category from step (iv)b according to a second predetermined equation to form a SNPpc composite value, wherein the combination according to the second predetermined equation allows omission of measurement data of a subset of at least 10%, and up to 30%, of the SNPpc when forming the SNPpc composite value; and
(vii) Combining the biomarker composite value and the SNPpc composite value according to a third predetermined equation to form an overall composite value.
US Pat. No. 10,427,998

COMPOSITIONS BASED ON 1,1,3,3-TETRACHLOROPROPENE

ARKEMA FRANCE, Colombes ...

1. A composition comprising:at least 99.5% by weight of 1,1,3,3-tetrachloropropene (F-1230za), or at least 99.5% by weight of a mixture comprising 1,1,3,3-tetrachloropropene and 1,3,3,3-tetrachloropropene (F-1230zd), and
at least one additional compound selected from the group consisting of chlorobutenes and chlorobutanes, wherein the amount of said additional compound or the total amount of said compounds represents a content of less than or equal to 500 ppm, in the composition.
US Pat. No. 10,428,000

DIVIDING WALL IN ETHANOL PRODUCTION PROCESS

CARGILL, INCORPORATED, W...

1. A process for the purification of ethanol comprising the steps of:a) Distilling an aqueous feed stream comprising water, ethanol in an amount below its azeotropic concentration, and 1 to 25,000 mg/l Absolute Alcohol (AA) higher alcohols comprising propanol and/or fusel alcohols in a distillation column comprising at least one dividing wall;
b) Collecting propanol building up on a feed side of the dividing wall and feeding said propanol into the column at an outlet side of the dividing wall; and
c) Collecting a stream having a higher purity in ethanol compared to the feed stream.
US Pat. No. 10,428,002

METHOD FOR MANUFACTURING 1,4-BIS (4-PHENOXYBENZOYL)BENZENE IN SUPERSATURATION CONDITIONS

ARKEMA FRANCE, Colombes ...

1. A method for manufacturing 1,4-bis(4-phenoxybenzoyl)benzene, comprising:providing a reactant mixture comprising terephthaloyl chloride, diphenyl ether and a Lewis acid in a solvent;
reacting the terephthaloyl chloride with the diphenyl ether, so as to obtain a product mixture comprising a 1,4-bis(4-phenoxybenzoyl)benzene-Lewis acid complex;wherein the 1,4-bis(4-phenoxybenzoyl)benzene-Lewis acid complex is dissolved in the solvent at a 1,4-bis(4-phenoxybenzoyl)benzene weight concentration in the solvent which is higher than the saturation limit of the 1,4-bis(4-phenoxybenzoyl)benzene-Lewis acid complex during at least part of the step of reacting terephthaloyl chloride with diphenyl ether.
US Pat. No. 10,426,723

COSMETIC COMPOSITIONS

Mary Kay Inc., Addison, ...

1. A method of counteracting skin irritation caused by an exfoliant, the method comprising topically applying an effective amount of a skin exfoliation composition to skin in need thereof,wherein the composition comprises:
25 wt. % to 80 wt. % water,
2 wt. % to 20 wt. % of an alpha hydroxy acid to exfoliate the skin,
0.1 wt. % to 1.5 wt. % of 4-tert-butylcyclohexanol,
0.001 wt. % to 0.1 wt. % of an aqueous extract of plankton comprising an exopolysaccharide synthesized by Vibro alginolyticus,
0.001 wt. % to 0.1% wt. % of an aqueous extract of Phragmites communis,
0.001 wt. % to 0.1 wt. % of an aqueous extract of Poria cocos, and
0.0001 wt. % to 0.01 wt. % of an aqueous extract of Cucurbita pepo (pumpkin) seed.
US Pat. No. 10,428,003

METHOD FOR PRODUCING ACETIC ACID

DAICEL CORPORATION, Osak...

1. A method for producing acetic acid by reacting methanol with carbon monoxide in the presence of a catalyst system comprising a metal catalyst and methyl iodide, acetic acid, methyl acetate, and water, the method comprising:separating a process stream containing at least water, acetic acid, methyl iodide, and acetaldehyde into an aqueous phase and an organic phase, wherein an acetaldehyde concentration in a liquid to be subjected to the separation is not less than 0.026% by mass and a methyl acetate concentration in the liquid to be subjected to the separation step is 2.0 to 50% by mass, wherein
the following condition (i), the following condition (ii), the following condition (iii), and at least one of the following conditions (iv) and (v) are satisfied:
(i) an acetaldehyde concentration in the aqueous phase is not less than 0.045% by mass, and/or an acetaldehyde concentration in the organic phase is not less than 0.013% by mass;
(ii) a temperature at the time of the separation is not less than ?5° C.;
(iii) a methyl acetate concentration in the organic phase is 5.8% to 60% by mass;
(iv) an acetaldehyde distribution coefficient [{acetaldehyde concentration (% by mass) of the aqueous phase}/{acetaldehyde concentration (% by mass) of the organic phase}] is not more than 4.1; and
(v) a methyl acetate distribution coefficient [{methyl acetate concentration (% by mass) of the aqueous phase}/{methyl acetate concentration (% by mass) of the organic phase}] is not more than 0.53; and
separating and removing the acetaldehyde derived from the process stream, wherein at least a portion of the organic phase is treated.
US Pat. No. 10,428,004

METHOD FOR PRODUCING ACETIC ACID

DAICEL CORPORATION, Osak...

1. A method for producing acetic acid, comprising distilling a crude acetic acid solution containing acetic acid and an impurity having a higher boiling point than that of acetic acid to purify the acetic acid, wherein the method comprisescarbonylating methanol with carbon monoxide to produce acetic acid,
evaporating a reaction mixture obtained by the carbonylation to separate into a vapor stream and a residual liquid stream,
removing a lower boiling point component by distillation to separate the vapor stream into an overhead stream rich in lower boiling point component and a first acetic acid stream rich in acetic acid,
dehydrating the first acetic acid stream by distillation to separate into a second acetic acid stream more enriched with acetic acid than the first acetic acid stream, and a vapor of an overhead stream containing a larger amount of a component having a lower boiling point than that of acetic acid as compared with the second acetic acid stream, and
removing a higher boiling point component by distillation to separate the second acetic acid stream into a vapor as an overhead stream containing a larger amount of a component having a lower boiling point than that of acetic acid as compared with a bottom fraction, the bottom fraction containing a larger amount of a component having a higher boiling point than that of acetic acid as compared with the overhead stream, and a third acetic acid stream more enriched with acetic acid than the second acetic acid stream; and
wherein the distillation of the second acetic acid stream is performed under a condition involving a column bottom temperature of a distillation column of 70 to 165° C. and a column bottom pressure of the distillation column of not less than 0.01 MPaG and less than 0.255 MPaG, and
the bottom fraction of the distillation column has an acetate salt concentration of not more than 34% by mass, an acetic anhydride concentration of not more than 90% by mass, and a propionic acid concentration of not more than 90% by mass.
US Pat. No. 10,428,007

METHOD FOR PRODUCING UNSATURATED ALDEHYDE AND UNSATURATED CARBOXYLIC ACID

LG CHEM, LTD., Seoul (KR...

1. A method for producing unsaturated aldehydes and unsaturated carboxylic acids corresponding to a raw material in which at least one compound selected from propylene, isobutylene, t-butyl alcohol, and methyl-t-butyl ether is added as the raw material and subjected to gas phase contact oxidation with molecular oxygen or a molecular oxygen-containing gas, using a fixed-bed multistage heat medium circulating type of multi-tubular shell-and-tube reactor filled with a catalyst,wherein the multistage heat medium circulating type of multi-tubular shell-and-tube reactor includes a cylindrical shell, a plurality of tube sheets for separating the inside of the shell into a plurality of independent spaces, a baffle for dividing the plurality of independent spaces inside the shell into two spatially continuous zones, and a plurality of reaction tubes fixed to the inside of the shell while penetrating through the plurality of tube sheets and the baffle,
wherein, in the plurality of independent spaces inside the shell, heat transfer to the reaction tube is performed independently at a temperature of 280 to 400° C. by the flow of an independent heat medium,
wherein at least four spatially continuous fixed catalyst layer zones exist in the reaction tube, the fixed catalyst layer zones have high activity in the direction from an inlet to an outlet of the reaction tube, and the fixed catalyst layer zones include first to fourth fixed catalyst layer zones, and
wherein a length (L) and an outer diameter (D) of the catalyst decreases from the first to the fourth fixed catalyst layer zones.
US Pat. No. 10,431,853

RECHARGEABLE BATTERY FEATURES AND COMPONENTS

Apple Inc., Cupertino, C...

13. A battery comprising:a housing characterized by a first end and a second end opposite the first end, wherein the housing comprises a circumferential indentation proximate the first end, wherein the housing defines a first interior region between the first end and the circumferential indentation, and wherein the housing defines a second interior region between the circumferential indentation and the second end;
a set of electrodes located within the housing, wherein the set of electrodes is positioned within the second interior region of the housing;
a cap at least partially contained within the first interior region of the housing, wherein the cap is characterized by a first surface facing the set of electrodes;
a first electrode tab coupled with the set of electrodes at a first end of the electrode tab, wherein a first surface of the electrode tab is coupled with a surface of the cap at a second end of the electrode tab, wherein the second end of the electrode tab is contained within an insulative material, wherein a first window is defined within the insulative material along the first surface of the electrode tab, and wherein the first end of the electrode tab is characterized by chamfered edges;
a second electrode tab coupled between the set of electrodes and an interior surface of the housing, wherein the electrode tab is coupled with the housing in the second interior region proximate the circumferential indentation; and
a first insulator positioned within the housing, wherein the first insulator extends across the circumferential indentation from the cap to the set of electrodes, wherein the first insulator is characterized by a first outer radius at a first end proximate the cap, and wherein the first insulator is characterized by a second outer radius greater than the first outer radius at a second end proximate the set of electrodes.
US Pat. No. 10,426,733

PHARMACEUTICAL COMPOSITION COMPRISING IBRUTINIB

Synthon B.V., Nijmegen (...

1. A tablet composition comprising ibrutinib and one or more pharmaceutically acceptable excipients, wherein:ibrutinib is form C, having characteristic peaks in the X-ray powder diffraction pattern at the following 2 theta (±0.2) angles: 6.9°, 18.2°, 19.2°, 19.6° and 23.0°, measured using a Cu K? radiation, and
the composition is free of surfactant, and
the composition exhibits a dissolution rate of at least 65% in 20 minutes when tested in 900 ml 0.01 N hydrochloric acid pH 2.0 (+1% polysorbate 20) at 37° C., 75 rpm and/or in 900 ml phosphate buffer pH 6.8 (+3% polysorbate 20) at 37° C., 75 rpm in a USP apparatus II.
US Pat. No. 10,426,734

TASTE MASKING DRUG FORMULATIONS

ORBIS BIOSCIENCES, INC., ...

1. A composition comprising: a microcapsule comprising a core portion and a shell portion, wherein the core portion comprises an active pharmaceutical ingredient and a hydrophilic excipient, wherein the shell portion comprises a mixture of a hydrophobic matrix and from about 1% to 25% by weight of a pH-responsive material, wherein the pH-responsive material is insoluble at a pH of greater than 5.0 or is otherwise insoluble in saliva and is soluble at a pH of less than 5.0, the balance of the shell portion comprising the hydrophobic matrix, wherein the hydrophobic matrix comprises one or more hydrophobic matrix components, wherein at least one of the hydrophobic matrix components is a wax or a lipid, wherein the shell portion encapsulates the core portion.
US Pat. No. 10,426,736

DELIVERING FUNCTIONAL NUCLEIC ACIDS TO MAMMALIAN CELLS VIA BACTERIALLY-DERIVED, INTACT MINICELLS

ENGENEIC MOLECULAR DELIVE...

1. A composition comprising:(a) a first intact, bacterially derived minicell that contains a a functional nucleic acid molecule or a plasmid comprising a segment that encodes a functional nucleic acid molecule, wherein the functional nucleic acid molecule targets (i) a transcript encoding a protein that contributes to apoptosis resistance in tumor cells or (ii) a transcript encoding a protein that contributes to neoplasticity in tumor cells;
(b) a second intact, bacterially derived minicell that is separate from the first minicell and that contains a drug; and
(c) a pharmaceutically acceptable carrier for each of (a) and (b).
US Pat. No. 10,431,349

METHOD FOR MAKING CROSSLINKED FLUOROPOLYMER COMPOSITIONS CONTAINING LOW LEVEL OF EXTRACTABLE FLUORIDES

Daikin America, Inc., Or...

1. A method of making a crosslinked ethylene tetrafluoroethylene (ETFE) copolymer with enhanced abrasion resistance and heat resistance, the method comprising:(a) providing a composition comprising:
(i) a fluoropolymer fraction consisting essentially of ETFE;
(ii) a metal oxide selected from the group consisting of ZnO and MgO; and
(iii) at least 1% w/w triallyl isocyanurate (TAIC) as a crosslinking agent; and
(b) exposing the composition to at least about 5 Mrad (50 kGy) ionizing radiation; wherein the level of extractable fluoride ions in the crosslinked ETFE copolymer is less than about 150 ppm w/w.
US Pat. No. 10,428,275

METHOD FOR MANUFACTURING LIQUID CRYSTAL DISPLAY DEVICE AND LIQUID CRYSTAL DISPLAY DEVICE

JNC CORPORATION, Tokyo (...

1. A method for manufacturing a liquid crystal display device, wherein, upon manufacturing the liquid crystal display device including a pair of substrates that have no alignment film and arranged to face each other, and including a liquid crystal composition containing a liquid crystal compound and a polymerizable compound as a liquid crystal layer formed between the substrates formed of an electrode group formed on either one or both of surfaces faced by each of the pair of substrates, in which at least one of the polymerizable compounds is a compound having a polar anchor group, wherein the polymerizable compound is allowed to react under conditions of 10 or more in an accumulated light quantity ratio of 313 nm/254 nm at 254 nanometers and 313 nanometers to form an alignment control layer.
US Pat. No. 10,428,278

METHOD AND SYSTEM FOR PRODUCING AROMATIC HYDROCARBONS FROM A RENEWABLE RESOURCE

Chevron Phillips Chemical...

1. A method for producing a bio-derived aromatic hydrocarbon, comprising:a) contacting a biomass with hydrogen in the presence of a hydrodeoxygenation catalyst in at least one hydrodeoxygenation reactor unit, under conditions that produce a bio-derived feedstock further comprising paraffinic, naphthenic, and/or olefinic hydrocarbons;
b) introducing the bio-derived feedstock into at least one aromatization reactor unit and contacting the bio-derived feedstock with an aromatization catalyst under conditions that produce an aromatic hydrocarbon and hydrogen; and
c) providing at least a portion of the hydrogen produced in the at least one aromatization reactor to the at least one hydrodeoxygenation reactor for contacting the biomass,
wherein the biomass comprises a cellulose, a sugar, a starch, a lignocellulose, a hemicellulose, a lignin, or combinations thereof.
US Pat. No. 10,426,743

TOPICAL PHARMACEUTICAL COMPOSITIONS

DERMAVANT SCIENCES GMBH, ...

1. A method of treating an inflammatory disease or disorder in a patient in need thereof, the method comprising administering to said patient a topical pharmaceutical oil-in-water emulsion composition comprising:3,5-dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof in an amount of about 0.05% to about 2% by weight, based on the total weight of the composition;
an oil phase comprising medium chain triglycerides of a carbon length from six to twelve carbons in an amount of about 2% to about 30% by weight, based on the total weight of the composition;
a water phase;
a surfactant in an amount of about 1% to about 20% by weight, based on the total weight of the composition, wherein the surfactant comprises at least one non-ionic emulsifying wax NF; and
a dermatologically acceptable excipient selected from the group consisting of an antioxidant, a pH adjusting agent, a chelating agent, a preservative, a co-solvent and combinations thereof;
wherein the 3,5-dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof is solubilized in the oil phase and is the only active ingredient in the oil phase;
wherein the oil phase is substantially free of petrolatum and mineral oil;
wherein the oil-in-water emulsion is homogeneous; and
wherein the average droplet size of the oil phase is from about 0.1 microns to about 35 microns.
US Pat. No. 10,426,744

ANTI-FUNGAL COMPOSITIONS FOR TREATING NAILS AND METHODS FOR FABRICATING AND USING THEREOF

Harrow Health, Inc., San...

1. A pharmaceutical composition for treating, mitigating or preventing fungal nail diseases, disorders or pathologies, the composition consisting of:(a) a therapeutically effective quantity of an antifungal component consisting of:
(a1) at least one functionalized allylamine compound;
(a2) at least one functionalized triazole compound; and
(a3) at least one functionalized imidazole compound;
(b) a therapeutically effective quantity of at least one pharmaceutically acceptable penetration enhancing compound selected from the group consisting of ibuprofen and ?-cyclodextrin; and
(c) at least one pharmaceutically acceptable excipient that is compatible with the antifungal component and the penetration enhancing compound, wherein the pharmaceutically acceptable excipient is selected from group consisting of glycol and benzyl alcohol,
wherein the composition has a pH in a range between about 2.0 and 6.5, and wherein the composition is formulated in a form that is suitable for topical administration.
US Pat. No. 10,426,746

METHODS OF TREATING DEVELOPMENTAL DISORDERS WITH BIGUANIDES

OVID THERAPEUTICS INC., ...

1. A method of treating Fragile X syndrome comprising administering to a patient in need thereof a therapeutically effective amount of a biguanide or a pharmaceutically acceptable salt thereof, the biguanide selected from the group consisting of metformin, buformin and phenformin, wherein the method provides improvement in one or more symptoms of Fragile X syndrome in the patient.
US Pat. No. 10,426,748

COMPOSITIONS AND METHODS FOR TREATING CHRONIC INFLAMMATION AND INFLAMMATORY DISEASES

Infirst Healthcare Limite...

1. A pharmaceutical composition comprising:a) a therapeutically effective amount of an ibuprofen;
b) less than about 20% by weight of the composition of a pharmaceutically-acceptable liquid polyethylene glycol (PEG) polymer; and
c) at least 50% by weight of the composition of pharmaceutically-acceptable glycerolipids comprising monoglycerides, diglycerides, and triglycerides;
wherein the pharmaceutical composition is formulated to have a melting point temperature of about 25° C. or higher.
US Pat. No. 10,427,005

GOLF BALLS INCORPORATING POLYCYCLOPENTENE RUBBER

Acushnet Company, Fairha...

1. A golf ball having an intermediate layer comprising a polycyclopentene rubber composition comprised of at least one polycyclopentene rubber, wherein each polycyclopentene rubber is a linear, unbranched chain polymer and disposed between a core layer that does not contain the at least one polycyclopentene rubber and at least one cover layer comprising a thermoset or thermoplastic material.
US Pat. No. 10,426,754

CRYSTALLINE FORM OF ANAVEX2-73 FOR THE TREATMENT OF ALZHEIMER'S DISEASE

ANAVEX LIFE SCIENCES CORP...

13. A method of treating Alzheimer's disease in a subject comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition according to claim 1; and wherein said pharmaceutical composition is administered according to an intermittent dosing regimen of at least two cycles, each cycle comprising (a) a dosing period during which a therapeutically effective amount of said pharmaceutical composition is administered to said patient and, thereafter, (b) a resting period.
US Pat. No. 10,428,038

SINGLE STEP PROCESS FOR THE SYNTHESIS OF FURFURYL ETHYL ETHER

COUNCIL OF SCIENTIFIC AND...

1. A single step process for the synthesis of furfuryl ethyl ether comprises refluxing the reaction mixture of furfuryl alcohol, ethanol and Zr incorporated SBA-15 catalyst at temperature in the range of 80 to 120° C. for the period in the range of 3 to 7 hrs to afford furfuryl ethyl ether, wherein selectivity of said reaction towards furfuryl ethyl ether is in the range of 85 to 95%.
US Pat. No. 10,428,294

CONTROLLED RELEASE MICROCAPSULES

ENCAPSYS, LLC, Appleton,...

1. A method of making microcapsules whose shell wall comprises on one surface a first (meth)acrylate polymer and on its other surface a second (meth)acrylate polymer, said first (meth)acrylate polymer derived from an aqueous phase (meth)acrylate polymer wall forming composition (I) and said second (meth)acrylic polymer derived from an oil phase (meth)acrylate polymer wall forming composition (II), both the aqueous phase (meth)acrylate polymer wall forming composition (I) and the oil phase (meth)acrylate polymer wall forming composition (II) comprising wall forming materials, and an intermediate region comprising an interpenetrating network and/or copolymer of the two wall forming compositions, said method comprising:(i) forming an oil-in-water or a water-in-oil emulsion of the two (meth)acrylate polymer wall forming compositions,
(ii) subjecting the emulsion to conditions for concurrently, at last in part, polymerizing the wall forming materials of each of the oil phase and aqueous phase, and
(iii) allowing the reaction to continue until the microcapsules of desired wall thickness are attained wherein said aqueous phase (meth)acrylate polymer wall forming composition (I) comprises one or more polyethylene glycol di(meth)acrylates, ethoxylated mono- or multi-functional (meth)acrylates, and/or (meth)acrylate monomers and/or oligomers.
US Pat. No. 10,431,380

BIAXIALLY STRETCHED POLYPROPYLENE FILM FOR CAPACITOR

OJI HOLDINGS CORPORATION,...

1. A biaxially stretched polypropylene film for capacitors, obtained by biaxially stretching a polypropylene resin,the polypropylene film having a crystallite size of 122 ? or less as determined by the Scherrer's equation from the half width of the reflection peak from (040) plane of ?-crystal measured by a wide angle X-ray diffraction method, and
the polypropylene film having a value of birefringence ?Nyz with respect to a thickness direction of 7.0×10?3 or more and 10.0×10?3 or less as measured by an optical birefringence measurement.
US Pat. No. 10,428,307

METHOD FOR CONVERTING MESENCHYMAL STEM CELLS INTO ENDOTHELIAL CELLS BY USING SPECIFIC TRANSCRIPTION FACTORS

The Catholic University o...

1. An in vitro method for converting mesenchymal stem cells into endothelial cells, the method comprising the steps of:(a) introducing lentiviral vectors comprising Oct4, Nanog, Tal1, and LMO2 genes into the mesenchymal stem cells; and
(b) culturing the transduced mesenchymal stem cells on a gelatin-coated plate under culture conditions comprising endothelial cell growth medium EGM2 and SB431542, wherein said culturing induces the conversion of the mesenchymal stem cells into endothelial cells.
US Pat. No. 10,428,311

METHOD FOR ENHANCING ACTIVITY OF LAMININ FRAGMENTS AS CELL CULTURE MATRIX

OSAKA UNIVERSITY, Osaka ...

5. A solution for coating a culture surface of a cell culture vessel with a laminin fragment or a variant thereof,the solution containing a laminin fragment or a variant thereof each having an integrin binding activity and a protein that is neither a laminin nor a laminin fragment,
the laminin fragment or a variant thereof being present at a concentration of 5 ?g/mL or lower,
the protein that is neither a laminin nor a laminin fragment being present at a concentration which is 100-fold or more that of the laminin fragment or a variant thereof and is 500 ?g/mL or higher,
the protein that is neither a laminin nor a laminin fragment is gelatin or serum albumin,
wherein the laminin fragment is a laminin E8 fragment, and
wherein the variant is a chimeric molecule in which the laminin E8 fragment is conjugated with a cell adhesion molecule or a growth factor binding molecule.
US Pat. No. 10,426,776

METHOD FOR TREATING CANCER PATIENTS WITH SEVERE RENAL IMPAIRMENT

TAIHO PHARMACEUTICAL CO.,...

1. A method for treating cancer which is one of gastrointestinal cancer, large bowel cancer and breast cancer, comprising:detecting a creatinine clearance of a patient; and
orally administering to the patient with a creatinine clearance of less than 30 mL/min a combination drug comprising ?,?,?-trifluorothymidine (FTD) and 5-chloro-6-[(2-iminopyrrolidine-1-yl)methyl]pyrimidine-2,4(1H,3H)-dione hydrochloride in a molar ratio of 1:0.5, a daily dose of 30 to 40 mg/m2/day as FTD-equivalent, divided into two to four portions for administration.
US Pat. No. 10,428,313

CHIMERIC WEST NILE/DENGUE VIRUSES AND METHODS OF USE

The United States of Amer...

1. A nucleic acid chimera comprising:a first nucleic acid molecule comprising a 5? non-coding region, a nucleic acid encoding non-structural proteins and a C protein, and a 3? non-coding region from a West Nile virus genome, wherein the C protein comprises a signal sequence 18 amino acids long comprising a 5? portion of a prM signal sequence from the West Nile virus genome and a 3? portion of a prM signal sequence from a Dengue virus genome; and
a second nucleic acid molecule operably linked to the first nucleic acid molecule, encoding at least a portion of a prM protein and E protein from a Dengue virus genome, wherein the second nucleic acid is 3? to the portion of the prM signal sequence from the Dengue virus genome and 5? to the non-structural proteins and 3? non-coding region from the West Nile virus.
US Pat. No. 10,426,778

PROPHYLACTIC AGENT AND/OR THERAPEUTIC AGENT FOR DIFFUSE LARGE B-CELL LYMPHOMA

ONO PHARMACEUTICAL CO., L...

1. A method of treating B-cell non-Hodgkin's lymphoma comprising: administering to a human in need thereof a pharmaceutically effective amount of 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one or a salt thereof and at least one additional anticancer agent; wherein the at least one additional anticancer agent comprises a PI3K inhibitor, and wherein the PI3K inhibitor is CAL-101.
US Pat. No. 10,428,316

IMMORTALISED CHICKEN EMBRYO FIBROBLASTS

Intervet Inc., Madison, ...

1. A stably transfected immortalized chicken embryo fibroblast (CEF), wherein said immortalized CEF (i) expresses an SV40 T antigen, (ii) expresses a chicken telomerase (cTERT) under the control of a heterologous promoter, and (iii) does not comprise an exogenous retroviral Long Terminal Repeat (LTR) DNA.
US Pat. No. 10,428,317

LIGHT-EMITTING MOLECULES

Gene Stream Pty Ltd, Cit...

1. A method of modifying an isolated, synthetic, recombinant or purified copepod luciferase polypeptide comprising an amino acid sequence at least 80% identical to SEQ ID NO: 792 or SEQ ID NO: 2, the method comprisingaltering the copepod luciferase polypeptide such that it comprises a modification consisting of:(a) at least one BC motif, wherein B is selected from basic amino acid residues and C is a conserved cysteine or modified form thereof; and the BC motif is selected from the group consisting of BCA at C5, C6, and/or C9, BCA? at C5, C6, and/or C9, and BCAD at C5, C6, and/or C9, wherein ? is selected from a small amino acid residue or an acidic amino acid residue, A is alanine or modified form thereof, D is aspartate or a modified form thereof, and C5, C6, and C9 are conserved cysteines of consensus SEQ ID NO: 905;and at least one of:
(i) L, or modified form thereof, at at least one position corresponding to positions 85 or 98 of consensus SEQ ID NO: 905; and
(ii) a deletion in whole or in part of an amino acid sequence, wherein the amino acid sequence spans downstream of the signal peptide sequence and upstream of the amino acid residue at a position corresponding to position 85 of consensus SEQ ID NO: 905; or(b) at least one BC motif, wherein B is selected from basic amino acid residues and C is a conserved cysteine or modified form thereof; and the BC motif is selected from the group consisting of BCA at C5 and/or C9, BCAD at C5, and/or C9, and BCA at C5and/or C9, wherein ? is selected from a small amino acid residue or an acidic amino acid residue, A is alanine or modified form thereof, D is aspartate or modified form thereof, and C5, and C9 are conserved cysteines of consensus SEQ ID NO: 905,and optionally, further comprising at least one of:
(i) L, or modified form thereof, at at least one position corresponding to positions 85 or 98 of consensus SEQ ID NO: 905; and
(ii) a deletion in whole or in part of an amino acid sequence, wherein the amino acid sequence spans downstream of the signal peptide sequence and upstream of the amino acid residue at a position corresponding to position 85 of consensus SEQ ID NO: 905;
thereby producing a modified copepod luciferase polypeptide,wherein the modified polypeptide in (a) comprises at least one motif selected from the group consisting of:(i) a BCA motif at at least one position corresponding to conserved cysteines C5, C6, and C9; and
(ii) a BCA? motif at at least one position corresponding to conserved cysteines C5, C6, and C9; and
a deletion in whole or in part of an amino acid sequence, wherein the amino acid sequence spans downstream of the signal peptide sequence and upstream of the amino acid residue at the position corresponding to position 85 of consensus SEQ ID NO: 905;or in (b) comprises at least one motif selected from the group consisting of:(i) a BCA motif at at least one position corresponding to conserved cysteines C5 and C9; and
(ii) a BCA? motif at at least one position corresponding to conserved cysteines C5 and C9; and a deletion in whole or in part of an amino acid sequence, wherein the amino acid sequence spans downstream of the signal peptide sequence and upstream of the amino acid residue at the position corresponding to position 85 of consensus SEQ ID NO: 905.
US Pat. No. 10,428,324

ACOUSTIC MANIPULATION OF FLUIDS BASED ON EIGENFREQUENCY

TRIAD NATIONAL SECURITY, ...

1. A system for acoustic fluid manipulation, the system comprising:an acoustic resonator device comprising:
a fluid chamber that receives a volume of a fluid, the volume of the fluid including a phase-separate material, wherein one or more eigenfrequencies characterize at least the volume of the fluid;
a carrier surface forming at least a first sidewall portion of the fluid chamber;
a reflector surface forming at least a second sidewall portion of the fluid chamber; and
a transducer coupled to the carrier surface, wherein receipt of electricity at the transducer from a voltage source triggers emission of an acoustic output by the transducer, the acoustic output thereby passing through the carrier surface and the fluid chamber toward the reflector surface, the transmission of the acoustic wave thereby exciting at least the volume of the fluid; and
a controller configured to track the one or more eigenfrequencies over time in response to changes in one or more properties of the volume of the fluid and adjust the output frequency of the acoustic output by the transducer based on the one or more tracked eigenfrequencies,
wherein the controller is configured to adjust the output frequency toward a frequency that is near one of the one or more tracked eigenfrequencies and away from an eigenfrequency of the acoustic resonator device when the acoustic resonator device is empty.
US Pat. No. 10,428,326

METHODS AND SYSTEMS FOR DROPLET-BASED SINGLE CELL BARCODING

10X GENOMICS, INC., Plea...

1. A method for processing or analyzing one or more components from a cellular sample, comprising:(a) providing a plurality of cell beads and a plurality of barcode beads, wherein (i) a cell bead of said plurality of cell beads comprises a cell, wherein said cell comprises a nucleic acid molecule in an interior region of said cell, and (ii) a barcode bead of said plurality of barcode beads comprises a plurality of nucleic acid barcode molecules, wherein nucleic acid barcode molecules of said plurality of nucleic acid barcode molecules comprise a common barcode sequence;
(b) subjecting said plurality of cell beads to bulk processing, which bulk processing comprises: (i) rendering said nucleic acid molecule accessible to a species external to said interior region and (ii) denaturing said nucleic acid molecule to generate a denatured nucleic acid molecule in said cell bead; and
(c) partitioning said plurality of cell beads and said plurality of barcode beads into a plurality of partitions, wherein upon partitioning, a partition of said plurality of partitions comprises said cell bead and said barcode bead.
US Pat. No. 10,428,327

COMPOSITIONS AND METHODS FOR ENHANCING HOMOLOGOUS RECOMBINATION

LIFE TECHNOLOGIES CORPORA...

1. A method for performing homologous recombination, the method comprising:(a) generating a double-stranded break in a nucleic acid molecule present inside a cell to produce a cleaved nucleic acid molecule, and
(b) contacting the cleaved nucleic acid molecule generated in (a) with a partially double-stranded donor nucleic acid molecule,
wherein the cleaved nucleic acid molecule and the donor nucleic acid molecule each contain matched termini on at least one end,
wherein the matched termini on at least one end of the cleaved nucleic acid molecule and on at least one end the donor nucleic acid molecule is at least ten nucleotides in length,
wherein the matched terminus on at least one end of the cleaved nucleic acid molecule is double-stranded and the matched terminus on at least one end of the donor nucleic acid molecule comprises a 3? single-stranded overhang.
US Pat. No. 10,426,793

MEDICATION AND APPLICATION FOR TREATMENT OF HYPERTENSION BASED ON ANION AND TRADITIONAL CHINESE MEDICINE

1. A medicament for treatment of hypertension comprising: 9˜30% by percentage weight of Scutellaria baicalensis, 3˜9% by percentage weight of Radix Bupleuri, 3˜12% by percentage weight of Uncaria tomentosa (cat's claw), 3˜9% by percentage weight of Ginseng, 15˜25% by percentage weight of Cynanchum mooreanum Hemsl., 3˜9% by percentage weight of Cordyceps sinensis (Berk.) Sacc., 10˜15% by percentage weight of Flastem Milkvetch Seed, 9˜15% by percentage weight of Dermatocarpon miniatum (L.) Mann. [Lichen miniatius L.], 10˜15% by percentage weight of Millettia dielsiana, 10˜15% by percentage weight of stem or root of Dalbergia hancei Benth. (Leguminosae), 0.1˜1% by percentage weight of anion powder and 0.1˜1% by percentage weight of far-infrared nano powder, wherein the particle size of said anion powder and said far-infrared nano powder is 2000˜4000 mesh, and wherein said medicament for treatment of hypertension is in the form of a pill.
US Pat. No. 10,428,329

COMPOSITIONS AND METHODS USING CAPSIDS RESISTANT TO HYDROLASES

APSE, INC., St. Louis, M...

1. A method for producing double stranded RNA comprising (a) purifying from a bacterial lysate:a first composition comprising a virus-like particle (VLP) comprising protease resistant capsid proteins enclosing a heterologous cargo molecule, wherein the heterologous cargo molecule comprises a long single stranded sense RNA having more than 30 nucleotides, the cargo molecule further comprising a capsid specific packing sequence, and
a second composition comprising a VLP comprising protease resistant capsid proteins enclosing a heterologous cargo molecule, wherein the heterologous cargo molecule comprises a long single stranded antisense RNA complementary to the sense strand RNA of the first composition, said single stranded antisense RNA having more than 30 nucleotides, the cargo molecule further comprising a capsid specific packing sequence;
(b) mixing equal amounts of each composition;
(c) isolating the heterologous cargo molecules thereof;
(d) annealing the heterologous cargo molecules to form a double stranded RNA molecule;
(e) isolating the double stranded RNA molecule.
US Pat. No. 10,426,794

METHODS AND COMPOSITIONS OF TREATING AUTOIMMUNE DISEASES

1. A method of generating an immunosuppressive dendritic cell comprising: contacting a dendritic cell with an effective amount of an IL-27 polypeptide agonist and an effective amount of an extracellular ATP degrading enzyme.
US Pat. No. 10,426,795

USE OF PRETALPHA OR FUNCTIONAL VARIANT THEREOF FOR EXPANDING TCRALPHA DEFICIENT T CELLS

CELLECTIS, Paris (FR)

1. An isolated TCRalpha deficient primary human T cell,wherein the TCRalpha gene in the T cell has been inactivated by introducing a rare-cutting endonuclease that induces a DNA cleavage within the TCRalpha gene,
comprising an exogenous nucleic acid encoding an exogenous pTalpha polypeptide that supports CD3 surface expression and supports expansion of the TCR-deficient primary T cell using stimulatory anti-CD3/CD28 antibodies.
US Pat. No. 10,426,796

COMPOSITIONS FOR BIOLOGICAL SYSTEMS AND METHODS FOR PREPARING AND USING THE SAME

SMART Surgical, Inc., Bo...

1. A composition for performing a medical therapy, comprising:a low pH fluid base, wherein the low pH fluid base comprises dextrose;
mononuclear cells obtained from human umbilical cord blood; and
albumin, wherein the concentration of albumin is between about 10 mg/ml and about 150 mg/ml, and wherein the composition is configured for implantation within a human subject.
US Pat. No. 10,428,332

HYBRID IMMUNOGLOBULINS WITH MOVING PARTS

1. A process of making a product comprising:a) transfecting a cell with a recombinant nucleic acid which encodes a chimeric polypeptide comprising, from its N terminus to its C terminus,
(i) an N-terminal signal sequence, contiguous with
(ii) such stretch of consecutive amino acids capable of forming a disulfide bond, contiguous with
(iii) a C-terminal intein-containing binding domain,
under conditions such that:
(i) the cell expresses the chimeric polypeptide;
(ii) the N-terminal signal sequence is cleaved from the chimeric polypeptide, so as to produce a second chimeric polypeptide comprising the stretch of consecutive amino acids that is capable of forming a disulfide bond contiguous with the C-terminal intein-containing binding domain; and
(iii) the cell secretes the second chimeric polypeptide,
b) isolating the secreted second chimeric polypeptide produced in step (a);
c) treating the second chimeric polypeptide from step (b) with a cysteine or selenocysteine, so as to cause:
(i) thio-mediated cleavage of the C-terminal intein-containing binding domain from the stretch of consecutive amino acids; and
(ii) ligation of the cysteine or selenocysteine to such stretch of consecutive amino acids within such second chimeric polypeptide, at the C-terminal side thereof;
d) recovering the product of step (c) which is the stretch of consecutive amino acids comprising at its C-terminal side the additional cysteine or selenocysteine, and
e) then either:
(i) combining the product recovered in step (d) with a second product made using the process of steps (a)-(d) under conditions resulting in the formation of an —S—S—, —S—Se—, —Se—Se—, or —Se—S— bond between the respective C-terminal residues of the first product and the second product;
(ii) combining the product recovered in step (d) with a second, different stretch of consecutive amino acids comprising an N-terminal S-terminus or Se-terminus, under conditions resulting in the formation of an —S—S—, —S—Se—, —Se—Se—, or —Se—S— bond between the C terminus of the product and the N-terminal S-terminus or Se-terminus of the second, different stretch of consecutive amino acids; or
(iii) combining the product recovered in step (d) with a solid surface under conditions resulting in attachment of the product to such surface at its C-terminus, wherein the attachment is mediated by an —S—S—, —S—Se—, —Se—Se—, or —Se—S— bond formed between the cysteine or selenocysteine of the product and a cysteine or selenocysteine of the solid surface.
US Pat. No. 10,426,797

COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ANTI-CD33 IMMUNOTHERAPY

LENTIGEN TECHNOLOGY, INC....

1. An isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR) comprising, from N-terminus to C-terminus:(i) at least one extracellular antigen binding domain comprising a CD33 antigen binding domain encoded by the nucleotide sequence consisting of SEQ ID NO. 1, 3, 5, 7, 9, or 11:
(ii) a transmembrane domain comprising a transmembrane domain of a protein selected from the group consisting of the T-cell receptor (TCR) alpha chain, the TCR betachain, the TCR zeta chain, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 and CD154, or any combination thereof;
(iii) at least one costimulatory domain comprising a functional signaling domain selected from the group consisting of OX40, CD70, CD27, CD28, CD5, ICAM-1, LFA-1 (CD11a/CD18), ICOS (CD278), DAP10, DAP12, and 4-1BB (CD137), or any combination thereof; and
(iv) an intracellular signaling domain comprising a functional domain selected from the group consisting of a 4-1BB (CD137); CD28, and CD3 zeta signaling domain, or a combination thereof.
US Pat. No. 10,426,798

MODULATABLE SWITCH FOR SELECTION OF DONOR MODIFIED CELLS

Calimmune, Inc., Tucson,...

1. A method of providing benefits of a lymphocyte infusion to a patient in need of treatment thereof comprising:(a) generating HPRT deficient lymphocytes from a donor sample;
(b) positively selecting for the HPRT deficient lymphocytes ex vivo to provide a population of modified lymphocytes; and
(c) administering the population of modified lymphocytes to the patient following an administration of an HSC graft to the patient,
wherein the positive selection comprises contacting the generated HPRT deficient lymphocytes with a purine analog and an inhibitor of xanthine oxidase.
US Pat. No. 10,426,799

METHODS FOR PRODUCTION OF PLATELETS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF

Astellas Institute for Re...

1. A method for producing human megakaryocytes comprising:(a) culturing human pluripotent stem cells under an adherent condition in culture medium that comprises bone morphogenetic protein 4, basic fibroblast growth factor, and vascular endothelial growth factor to form human hemogenic endothelial cells;
(b) culturing the human hemogenic endothelial cells in culture medium that comprises two or more factors selected from thrombopoietin, interleukin-3, and interleukin-6 to form human megakaryocyte progenitors; and
(c) culturing the human megakaryocyte progenitors under a non-adherent culture condition in culture medium that comprises thrombopoietin and one or more factor(s) selected from stem cell factor, interleukin-6, interleukin-9, and a ROCK inhibitor to form human megakaryocytes.
US Pat. No. 10,428,335

YEAST CELLS EXPRESSING TAR DNA-BINDING PROTEIN 43 AND USES THEREFOR

Whitehead Institute for B...

1. A method of identifying a genetic suppressor or enhancer of TDP-43-induced toxicity, the method comprising:providing a yeast cell comprising an expression construct comprising a promoter operably linked to a nucleic acid encoding a polypeptide comprising a naturally-occurring TAR DNA-binding protein 43 (TDP-43) protein, wherein the naturally-occurring TDP-43 protein comprises an amino acid sequence that is at least 95% identical to amino acid residues 252-414 of SEQ ID NO:1, wherein expression of the nucleic acid and production of the polypeptide results in a decrease in growth or viability of the cell, wherein the yeast cell has been genetically modified to overexpress a gene;
culturing the yeast cell under conditions that allow for expression of the polypeptide at a level that, in the absence of overexpression of the gene, is sufficient to induce toxicity in the yeast cell;
measuring cell growth or viability in the presence of overexpression of the gene; and
comparing cell growth or viability measured in the presence of overexpression of the gene to cell growth or viability in the absence of overexpression of the gene,
wherein (i) if cell growth or viability is increased in the presence of overexpression of the gene as compared to in the absence of overexpression of the gene, then the gene is identified as a genetic suppressor of TDP-43-induced toxicity, and (ii) if cell growth or viability is decreased in the presence of overexpression of the gene as compared to in the absence of overexpression of the gene, then the gene is identified as a genetic enhancer of TDP-43-induced toxicity.
US Pat. No. 10,428,336

METHOD FOR MODULATING PLANT GROWTH

The Australian National U...

1. A method for increasing, accelerating or increasing and accelerating non-root plant growth in a plant relative to a wild-type plant grown under the same conditions, said method comprising introducing at least one mutation or at least one exogenous nucleic acid into one or more plant cells which at least one mutation or nucleic acid results in:(i) decreased expression of one or more C-TERMINALLY ENCODED PEPTIDEs (CEPs), decreased expression of one or more CEP receptors, or decreased expression of one or more CEPs and one or more CEP receptors by cells of a plant regenerated from or comprising said one or more plant cells, wherein said at least one mutation is in a sequence encoding a CEP, a CEP receptor or an upstream sequence thereof or wherein said exogenous nucleic acid is either a CEP-encoding sequence or a CEP receptor-encoding sequence, or said exogenous nucleic acid modulates, or its product modulates expression of at least one endogenous CEP-encoding nucleic acid or CEP receptor-encoding nucleic acid, wherein said exogenous nucleic acid comprises a nucleic acid sequence homologous to, or complementary to at least a portion of the endogenous CEP-encoding or CEP receptor-encoding nucleic acid; or
(ii) reduced affinity of one or more CEPs for their respective CEP receptors, which reduced affinity arises through modifications in the CEP(s), CEP receptor(s) or in both expressed CEP(s) and CEP receptor(s)expressed by cells of a plant regenerated from or comprising said one or more plant cells, wherein said at least one mutation is in a sequence encoding a CEP or a CEP receptor, or wherein said exogenous nucleic acid is either a CEP-encoding sequence or a CEP receptor-encoding sequence,
wherein said CEP comprises a CEP domain comprising the amino acid sequence (X1)nX2X3X4X5X6PGX9SPGX13GX15 (SEQ ID NO:454), wherein n is 0 or 1,
X1 is selected from D, A, P, G, S, V, E, P, T, Q, I, N, K, and C;
X2 is selected from F, V, T, S, A, K, Y, R, G, I, Q, H, D, G, and W;
X3 is selected from R, A, Q, G, E, V, D, K, P, S, H, and Q;
X4 is selected from P, G, S, T, A, N, C, H, V, E, Y, and K;
X5 is selected from T, S, A, P, G, V, N, M, and I;
X6 is selected from T, N, A, G, P, D, K, S, V, Y, Q, E, C, and H;
X9 is selected from H, N, S, Y, P, R, T, G, V, F, Q, and D;
X13 is selected from I, V, and A; and
X15 is selected from H, and N.
US Pat. No. 10,428,337

BRASSICA NAPUS ACC OX PROMOTER IDENTIFIED BY MICROARRAY ANALYSIS

Dow AgroSciences LLC, In...

1. A method for expressing a heterologous coding sequence in a transgenic plant, the method comprising:transforming a plant cell with a gene expression cassette comprising a polynucleotide sequence comprising a sequence identity of at least 98% to SEQ ID NO:1 operably linked to the heterologous coding sequence, which is operably linked to a 3?-untranslated region;
isolating the transformed plant cell comprising the gene expression cassette;
regenerating the transformed plant cell into a transgenic plant; and,
obtaining the transgenic plant, wherein the transgenic plant comprises the gene expression cassette comprising the polynucleotide sequence comprising a sequence identity of at least 98% to SEQ ID NO:1.
US Pat. No. 10,426,802

METHOD FOR PRODUCING SHEET-SHAPED CELL CULTURE

TERUMO KABUSHIKI KAISHA, ...

1. A method for producing a sheet-shaped cell culture, comprising:proliferating myoblast cells;
freezing the proliferated myoblast cells;
thawing the frozen myoblast cells;
forming a sheet-shaped cell culture with the thawed myoblast cells on a culture substrate by seeding the myoblast cells on the culture substrate at a density at which the cells can form a sheet-shaped cell culture substantially without any proliferation on the culture substrate, and wherein the myoblast cells are not proliferated between the freezing of the myoblast cells and the forming of the sheet-shaped cell culture; and
removing the sheet-shaped cell culture from the culture substrate.
US Pat. No. 10,433,463

BULK AMORPHOUS ALLOY HEAT SINK

Crucible Intellectual Pro...

20. A heat sink comprising:a metal alloy structure of unitary construction comprising:
a first portion comprising a bulk solidifying amorphous alloy having an amorphous phase;
a second portion having a crystalline phase; and
nano- and/or micro-scale features embossed on a surface of the metal alloy structure; wherein
the heat sink is configured to transfer heat by natural convection by air or forced convection by air; and
the crystalline phase is formed along the surface of the metal alloy structure.
US Pat. No. 10,426,803

TOPICAL MEDICAMENT FOR SKIN AND MUCOSAL INJURIES

REV PHARMA CORP, Miami, ...

1. A method for treating epidermolysis bullosa (EB) comprising:a) applying to skin or mucosal surfaces of a patient in need of treatment for EB a dressing gauze or bandage without prior cleaning of said skin or mucosal surfaces, wherein distributed on said dressing is an effective amount of a composition containing: from about 15 to about 30 percent by weight of beeswax; petroleum jelly, cod liver oil, flax seed oil, grape seed oil, chia oil, an added vitamin selected from the group consisting of vitamin A, D and E; and a pharmaceutically acceptable excipient and a preservative;
b) removing said dressing at least twice per day without damaging the patient's skin or mucosal surfaces due to removal of the dressing.
US Pat. No. 10,428,339

SYNTHETIC BRASSICA-DERIVED CHLOROPLAST TRANSIT PEPTIDES

Dow AgroSciences LLC, In...

1. A nucleic acid molecule comprising a polynucleotide that encodes a chimeric protein comprising a synthetic chloroplast transit peptide (CTP) and a linked polypeptide, the amino acid sequence of the synthetic CTP selected from the group consisting of:(A) a first amino acid sequence between 25 and 41 amino acids in length, wherein the first amino acid sequence is at least 90% identical to a contiguous amino acid sequence of the same length in the first 41 amino acids of SEQ ID NO:1, linked to a second amino acid sequence between 25 and 41 amino acids in length, wherein the second amino acid sequence is at least 90% identical to a contiguous amino acid sequence of the same length in the last 41 amino acids of SEQ ID NO:2; and
(B) a first amino acid sequence between 25 and 41 amino acids in length, wherein the first amino acid sequence is at least 90% identical to a contiguous amino acid sequence of the same length in the first 41 amino acids of SEQ ID NO:2, linked to a second amino acid sequence between 25 and 41 amino acids in length, wherein the second amino acid sequence is at least 90% identical to a continuous amino acid sequence of the same length in the last 41 amino acids of SEQ ID NO:1.
US Pat. No. 10,426,804

PENTOSIDINE PRODUCTION INHIBITOR

Kabushiki Kaisha Yakult H...

1. A method for inhibiting pentosidine production in a human subject comprising contacting the human subject with a pentosidine production inhibitor composition that consists of a pharmaceutically acceptable carrier and a fraction of a supernatant, as an active ingredient, obtained from a fermentation product of a cultured medium containing a milk constituent with a lactic acid bacterium as an active ingredient, wherein the fraction has a molecular weight of not more than 20,000 Da,wherein a pentosidine production inhibition rate is 25% or higher when the concentration of the fraction is 0.05% by mass in terms of the dry solid content,
wherein the relative amount of pentosidine in a test sample prepared by combining a sample obtained from the human subject to a solution is determined by fluorescence and the pentosidine production inhibition rate (%) is given by [Math. 1]:
((Ec?Eb)?(Es?Eb))/(Ec?Eb)×100, wherein
Es is the fluorescence intensity of the test sample,
Ec is the fluorescence intensity of the control sample that does not contain pentosidine and contains the same solution as the test sample, and
Eb is the fluorescence intensity of a blank sample that does not include ribose, lysine and arginine.
US Pat. No. 10,428,340

PHYTASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM

Syngenta Participations A...

1. A transgenic plant comprising an isolated, synthetic or recombinant polynucleotide encoding a variant polypeptide of the amino acid sequence of SEQ ID NO: 2, wherein the variant polypeptide comprises at least one amino acid mutation selected from the group consisting of: T48F; T48H; T48I; T48K; T48L; T48M; T48V; T48W; T48Y; L50W; M51A; M51G; M51L; G67A; Y79H; Y79N; Y79S; Y79W; Q86H; P100A; S102A; S102Y; I107H; I107P; I108A; I108Q; I108R; I108S; I108Y; A109V; E113P; L126R; Q137F; Q137L; Q137V; Q137Y; D139Y; P145L; L146R; L146T; F147Y; N148K; N148M; N148R; P149N; L150T; L150Y; K151H; K151P; C155Y; L157C; L157P; V162L; V162T; T163P; L167S; G171M; G171S; S173G; S173H; S173V; I174F; I174P; V191A; L192F; F194L; S197G; S211 H; L216T; P217D; P217G; P217L; P217S; S218I; S218Y; A232P; L235I; A236H; A236T; L244S; Q246W; Q247H; A248L; A248T; P254S; G257A; G257R; H263P; W265L; N266P; L269I; L269T; H272W; A274F; A274I; A274L; A274T; A274V; Q275H; T282H; T291V; T291W; Q309P; P343E; P343I; P343L; P343N; P343R; P343V; N348K; N348W; G353C; Q377R; L379S; L379V; Q381S; S389H; S389V; G395E; G395I; G395L; G395Q; G395T; V422M; I427G; I427S; I427T; and A429P; andwherein the variant polypeptide comprising the at least one amino acid mutation is an amino acid sequence at least 95% identical to the amino acid sequence as set forth in SEQ ID NO:2; and
wherein the variant polypeptide has phytase activity and has decreased gastric stability when compared to the parent polypeptide of the amino acid sequence of SEQ ID NO: 2.
US Pat. No. 10,426,805

METHOD FOR PRODUCING LACTIC ACID BACTERIA CONTROLLING M CELLS

1. A method for producing lactic acid bacteria, Lactobacillus salivarius, having a filament form with a length in a range of 4 ?m to 10 ?m to control M cells, comprising:selecting Lactobacillus salivarius as a starting material; and
culturing the Lactobacillus salivarius in a lactose-free medium at a temperature in a range of 39° C. to 41° C.
US Pat. No. 10,428,341

TRANSGENIC POTATO PLANTS WITH INCREASED HYALURONAN PRODUCTION

BASF SE, Ludwigshafen am...

1. A genetically modified potato plant cell comprising a nucleic acid molecule coding for a hyaluronan synthase stably integrated into its genome and a foreign nucleic acid molecule coding for a protein having the enzymatic activity of a glutamine:fructose 6-phosphate amidotransferase (GFAT), wherein said plant cell has an increased activity of a protein having the activity of a GFAT compared to corresponding non genetically modified wild-type plant cells, and wherein said cell synthesizes an increased amount of hyaluronan compared to a plant cell having the activity of a hyaluronan synthase and no increased activity of a GFAT.
US Pat. No. 10,426,806

ANTI-OBESITY EFFECT OF BORAGO OFFICINALIS LINN. EXTRACTS TO PREVENT AND TREAT METABOLIC DISORDERS

1. A method for treating insulin resistance in a human in need thereof consisting essentially of administering to said human in need thereof an oral dose of 150 mg/kg or 300 mg/kg of an ethanolic extract of Borago officinalis, sibutramine, and orlistat to said human in need of treatment, wherein insulin resistance is reduced by an increase in insulin sensitivity in a metabolic disorder in said human in need thereof.
US Pat. No. 10,428,086

SOLVATED CRYSTAL FORM OF RIFAXIMIN, PRODUCTION, COMPOSITIONS AND USES THEREOF

ALFASIGMA S.P.A., Bologn...

1. A stable diethylene glycol monoethyl ether solvate crystalline form of rifaximin ?, wherein the crystalline form has a tetragonal crystal system, the space group is P41212 and the unit cell parameters are a=b=16.51 (1) ?; c=36,80(1) ?; ?=?=?=90°; V=10027(1) ?3 or by a X-ray diffraction spectra with peaks at values of angles 2?±0.1° of 5.9°; 9.0°; 12.9°; 15.4°; 18.8°; 22.8° and 23.4°, wherein the stable diethylene glycol monoethyl ether solvate crystalline form of rifaximin ? does not transform into other forms of rifaximin, and wherein the rifaximin ? has a Cmax value from 0 to 35 ng/ml; AUC0-8 h from 0 to 35 ng·h/ml and AUC0-tlast from 20 to 235 ng·h/ml.
US Pat. No. 10,426,807

BONE AND JOINT PROTECTION COMPOSITION AND USE THEREOF

INFINITUS (CHINA) COMPANY...


US Pat. No. 10,426,808

PLANT EXTRACTS HAVING ANTICOCCIDIAL ACTIVITY

KEMIN INDUSTRIES, INC., ...

1. A method of controlling coccidiosis in animals, comprising the step of administering a plant extract to the animal, said plant extract from a plant selected from the group consisting of Quercus infectoria and Rhus chinensis, said plant extract being administered to the animals in a dose of from about 0.1 to 50 ppm.
US Pat. No. 10,428,344

NUCLEOTIDE SEQUENCES AND CORRESPONDING POLYPEPTIDES CONFERRING MODIFIED PHENOTYPE CHARACTERISTICS IN PLANTS

CERES, INC., Thousand Oa...

1. A method of producing a plant, said method comprising growing a plant cell comprising an exogenous nucleic acid molecule, said exogenous nucleic acid molecule comprising a regulatory region operably linked to a nucleotide sequence encoding a polypeptide, said polypeptide comprising an amino acid sequence having 80 percent or greater sequence identity to the amino acid sequence of SEQ ID NO:5752, and wherein said plant has a difference in the level of low-nitrogen tolerance as compared to the corresponding level of low-nitrogen tolerance of a control plant that does not comprise said nucleic acid molecule.
US Pat. No. 10,426,809

NANOBIOCOMPOSITE FORMULATION FOR WOUND HEALING AND A PROCESS FOR THE PREPARATION THEREOF

1. A nanobiocomposite formulation (NCs) in ointment form comprising silver nanoparticles (AgNPs) and cellulose nanocrystals (CNCs) wherein the ratio of AgNPs and CNCs is in the range of 0.067%-0.4% w/w AgNPs: 7-8% w/w CNCs, and wherein the cellulose is derived from Syzygium cumini leaves.
US Pat. No. 10,428,089

METHOD FOR PRODUCING TRIALKYLGALLIUM COMPOUNDS AND THE USE THEREOF

1. A process for preparing a compound (A), the formulaRGaCl2 or a mixture of RGaCl2 with R2GaCl,
comprising the reaction steps of
a1) reacting gallium with a gaseous alkyl donor in the presence of an activator to form compound (A) at a pressure of 1.1 bar to 10 bar,
a2) and optionally isolating said compound (A) from the reaction mixture,
where R is branched or unbranched alkyl of 1 to 4 carbon atoms and
wherein the activator is selected from the group consisting of R2GaCl, R3Ga2Cl3, RGaCl2 and mixtures thereof, or is a mixture of R2GaCl and RGaCl2, or wherein the reaction product, compound (A), is itself used as activator.
US Pat. No. 10,428,346

NUCLEOTIDE SEQUENCES AND CORRESPONDING POLYPEPTIDES CONFERRING MODULATED GROWTH RATE AND BIOMASS IN PLANTS GROWN IN SALINE CONDITIONS

CERES, INC., Thousand Oa...

1. A food or feed product comprising a tissue from a transgenic plant, wherein the transgenic plant and said tissue comprise a recombinant nucleic acid molecule, wherein the recombinant nucleic acid molecule comprises:(a) a nucleotide sequence that encodes a protein comprising the amino acid sequence of SEQ ID NO: 154, and wherein expression of the nucleotide sequence in a plant increases salt stress tolerance as compared to a control plant of the same species lacking said nucleotide sequence;
(b) a nucleotide sequence comprising the polynucleotide sequence of SEQ ID NO: 153, wherein the polynucleotide sequence encodes the protein of SEQ ID NO:154; or
(c) a nucleotide sequence hybridizing to the full length complementary sequence of the nucleotide sequence as set forth in SEQ ID NO: 153 under high stringency conditions which comprise (i) hybridization at 42° C. in 50% formamide, 6×SSC or 6×SSPE, 0.05% Blotto or 5×Denhardt's Reagent, 100 g/ml denatured salmon sperm DNA, 0.05% SDS and washing at 65° C. first in 2×SSC, 0.1% SDS for at least 30 min to one hour and subsequently in 0.1×SSC, 0.5% SDS for at least 30 min to one hour; or (ii) hybridization at 65° C. in 6×SSC or 6×SSPE, 0.05% Blotto or 5×Denhardt's Reagent, 100 ?g/ml denatured salmon sperm DNA, 0.05% SDS and washing at 65° C. first in 2×SSC, 0.1% SDS for at least 30 min to one hour, and subsequently in 0.1×SSC, 0.5% SDS for at least 30 min to one hour and wherein said hybridizing nucleotide sequence encodes a protein which has the functional activity of SEQ ID NO: 154;
wherein said nucleotide sequence is operably linked to a heterologous promoter;
wherein the protein encoded by the nucleotide sequence is expressed in the transgenic plant; and
wherein expression of the protein encoded by said nucleotide sequence in the transgenic plant increases salt stress tolerance as compared to a control plant of the same species that does not comprise the recombinant nucleic acid molecule.
US Pat. No. 10,426,811

BANANA FERMENTATION PRODUCT AND MANUFACTURING METHOD AND USE OF THE SAME

TCI CO., LTD., Taipei (T...

1. A banana fermentation product, which is obtained by subjecting a banana pulp juice to a pre-fermentation and then a post-fermentation, wherein the pre-fermentation is conducted in the presence of Streptococcus thermophiles DSMZ 28121 strain and Saccharomyces cerevisiae ATCC 4126T strain and the post-fermentation is conducted in the presence of at least one of Acetobacter aceti TISTR 102 strain and Acetobacter aceti DSMZ 3508 strain, and wherein, the pre-fermentation is conducted at 30° C.±1° C. for 72 hours, and the post-fermentation is conducted at 30° C.±1° C. for 21 days.
US Pat. No. 10,428,347

HERBICIDE-DETOXIFYING ENZYMES AND USES THEREOF

Spogen Biotech Inc., St....

1. A composition comprising a carrier and an enzyme that comprises an amino acid sequence having 100% identity to SEQ ID NO: 251, wherein:the carrier comprises a preservative, a bactericide or a combination thereof; and/or
the composition further comprises a co-factor regenerating enzyme.
US Pat. No. 10,426,812

COMPOSITIONS AND METHODS FOR THE TREATMENT OF ORTHOPEDIC AILMENTS

K.L.R.M., LLC, San Pedro...

1. A method for treatment of bone fractures, loss of bone mineral content or bone density, comprising:administering a pharmaceutically effective amount of a composition over a sufficient period of time that results in an increase in bone formation and/or prevents a decrease in bone mineral density, wherein the composition comprises ginger or a ginger derivative, Muira puama, Paullinia cupana, and at least one of the consisting of L-arginine and L-citrulline that stimulates osteoblasts to increases production of NOS, nitric oxide production and cGMP resulting in bone formation.
US Pat. No. 10,427,068

WATER DISTILLING AND PURIFYING UNIT AND VARIANTS THEREOF

1. A method for distilling water, comprising:moving raw water into an evaporator;
pumping water into a liquid-driven condensing ejector;
discharging water vapor from a vapor outlet of the evaporator into a gas inlet of the condensing ejector;
condensing the water vapor into liquid in the ejector
conducting fluid from an outlet of the ejector into a heat exchanger; and
transferring heat from fluid conducted from the condensing ejector in the heat exchanger to the raw water entering the evaporator, wherein the fluid conducted from the condensing ejector that is pumped into the liquid-driven jet ejector as motive fluid is cooled in the heat exchanger.
US Pat. No. 10,428,092

PROCESS OF PRODUCING PHOSPHINOTHRICIN EMPLOYING NITRILASES

Strategic Enzyme Applicat...

1. An isolated nucleic acid molecule encoding an enzyme having nitrilase activity and catalyzing the hydrolysis of —CN to —COX, wherein X is —OH or —NH2, wherein the nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6.
US Pat. No. 10,428,348

REPRODUCTION OF FEMALE STERILITY LINES AND ITS APPLICATION IN HYBRID SEED PRODUCTION

Exalt State Holdings Limi...

1. A DNA construct, comprising:i) a first nucleotide sequence selected from the group consisting of OsFMS2 gene and OsFMS 1 gene;
ii) a second nucleotide sequence selected from a group consisting of maize ?-amylase gene, auxin gene, rot B gene, cytotoxin gene, diphtherin gene, DAM methylase gene, and PA gene;
iii) a third nucleotide sequence selected from the group consisting of chloromycetin resistance gene, hygromycin resistance gene, streptomycin resistance gene, miramycin resistance gene, sulfonamide resistance gene, glyphosate resistance gene, glufosinate resistance gene, red fluorescence protein gene, cyan fluorescent protein gene, yellow fluorescent protein gene, luciferase gene, green fluorescent protein gene, an anthocyanin p1 gene, and blue fluorescent protein gene, and
at least one regulatory nucleotide sequence that allows expression of the first, the second and the third nucleotide sequences in a plant,
wherein the OsFMS2 gene has a nucleotide sequence selected from the group consisting of SEQ ID NOS:1 and 2, and
wherein the OsFMS1 gene has a nucleotide sequence selected from the group consisting of SEQ ID NOS:17 and 18.
US Pat. No. 10,426,813

METHOD TO ENHANCE ENDURANCE

KYOWA HAKKO BIO CO., LTD....

1. A method of enhancing endurance during exercise of a dehydrated human subject, comprising the step of:administering an effective amount of alanyl-glutamine or a salt thereof to the dehydrated human subject in a single dose,
wherein the dehydrated human subject is at least dehydrated at the beginning of the exercise by a loss of more than 1.5% of the dehydrated human subject's baseline body mass, and
the exercise elicits the dehydrated human subject a workload of at least 75% of the dehydrated human subject's VO2, max.
US Pat. No. 10,427,069

PROCESS FOR UPGRADING BIOMASS DERIVED PRODUCTS USING LIQUID-LIQUID EXTRACTION

Inaeris Technologies, LLC...

1. A method comprising:a) contacting an extraction solvent with a first mixture to form a second mixture comprising an extract and a raffinate, said first mixture comprising process water that has been separated from reaction products comprising (1) bio-oil and (2) said process water, wherein said reaction products are produced from catalytic conversion of biomass at temperatures ranging from 300° C. to 1000° C., and wherein said process water comprises water and biomass derived carbon containing compounds including organics A and organics B, and further wherein:
said organics A comprise compounds selected from the group consisting of i) aldehydes, ii) ketones having from 3 to 4 carbon atoms per molecule, iii) carboxylic acids having from 2 to 3 carbon atoms per molecule, and iv) combinations thereof,
said organics B comprise compounds having at least four carbon atoms per molecule wherein said organics B are substantially free of: i) aldehydes, ii) ketones having from 3 to 4 carbon atoms per molecule, and iii) carboxylic acids having from 2 to 3 carbon atoms per molecule,
said extract and said raffinate are immiscible,
said extract comprises substantially all of said extraction solvent and substantially all of said organics B,
said raffinate comprises substantially all of said water and substantially all of said organics A, and
said extraction solvent has a dipole moment greater than about 1.0 debye, a density less than about 1.0, a water solubility at 20° C. of less than about 2.5 g/100 ml of water, and a boiling point in the range of from about 90 to about 300° F.;
b) separating said second mixture thereby forming an intermediate product stream comprising at least a portion of said extract and a waste water stream comprising substantially all of said raffinate, wherein said wastewater stream comprises less than about 0.5 wt % of said organics B; and
c) removing at least a portion of said extraction solvent from said intermediate product stream forming a recovered extraction solvent and a bio-oil product.
US Pat. No. 10,426,814

CHEMICAL REPROGRAMMING OF HUMAN GLIAL CELLS INTO NEURONS FOR BRAIN AND SPINAL CORD REPAIR

The Penn State Research F...

1. A method for generating neurons in the brain of an individual, wherein the individual is a mammal, comprising administering to the individual a combination of compounds that comprise at least four of compounds or functional analogs thereof or pharmaceutically acceptable salts thereof, wherein the compounds are:i) LDN193189
ii) CHIR99021,
iii) N-[(3,5-Difluorophenyl)acetyl]-L-alany-2-phenyl]glycine-I,1-methylethyl ester (DAPT), and
iv) SB431542,wherein the administering the compounds is cell and virus free, and wherein the administering is sufficient such that the neurons are generated.
US Pat. No. 10,428,350

METHODS AND COMPOSITIONS FOR THE ACTIVATION OF GAMMA-DELTA T-CELLS

American Gene Technologie...

1. A method of treating a cancer in a subject in need thereof, the method comprising administering or having administered a therapeutically-effective amount of an immunotherapy-based composition to the subject, wherein the immunotherapy-based composition is obtained from an immunotherapy-based viral delivery system comprising:(i) at least one helper plasmid comprising DNA sequences for expressing a functional protein derived from each of a gag, pol, and rev gene;
(ii) an envelope plasmid comprising a DNA sequence for expressing an envelope protein capable of infecting a target cell; and
(iii) a therapeutic vector comprising:
at least one encoded shRNA that, when expressed, inhibits production of farnesyl diphosphate synthase (FDPS) or,
at least one encoded microRNA that, when expressed, inhibits production of farnesyl diphosphate synthase (FDPS).
US Pat. No. 10,426,815

PREVENTION AND TREATMENT OF ITCH WITH AN MRGPR ANTAGONIST

The General Hospital Corp...

1. A method of preventing or treating itch or treating a disease or disorder having itch as a symptom or sensation associated with a disease or disorder in a subject, the method comprising administering a therapeutically effective amount of an MRG receptor antagonist to the subject, wherein the MRG receptor antagonist is a tri-peptide QWF (Gln-Trp-Phe) or an analog or a derivative thereof.
US Pat. No. 10,428,351

METHODS FOR TRANSDUCTION AND CELL PROCESSING

Juno Therapeutics, Inc., ...

1. A transduction method, the method comprising incubating, in an internal cavity of a centrifugal chamber, an input composition comprising cells and viral particles containing a recombinant viral vector, wherein:the centrifugal chamber comprises:
an end wall, a substantially rigid side wall extending from said end wall, and one or more opening, wherein at least a portion of said side wall surrounds said internal cavity and at least one of the one or more opening is capable of permitting intake of liquid or gas into said internal cavity and expression of liquid or gas from said cavity; and
a movable member capable of moving within the chamber to vary the internal volume of the internal cavity, whereby the internal cavity is a cavity of variable volume defined by said end wall, said substantially rigid side wall, and said movable member;
the centrifugal chamber is rotatable around an axis of rotation and is rotating around said axis of rotation during at least a portion of the incubation;
during at least a portion of the incubation in the chamber or during the rotation of the chamber, the liquid volume of the input composition occupies only a portion of the volume of the internal cavity of the chamber, the volume of the cavity during said at least a portion or during said rotation further comprising a gas; wherein prior to or during said incubation, effecting movement of the movable member and effecting intake of the gas into said internal cavity, thereby increasing the volume of the internal cavity of the chamber; and
wherein the method generates an output composition comprising a plurality of the cells transduced with the viral vector.
US Pat. No. 10,429,378

METHODS OF DIFFERENTIATING PREADIPOCYTES AND USES THEREOF

Board Of Supervisors Of L...

1. A method of transdifferentiating mammalian preadipocytes, the method comprising:(a) culturing mammalian preadipocytes;
(b) infecting the mammalian preadipocytes with a viral vector encoding Oct4 such that the mammalian preadipocytes overexpress Oct4;
(c) culturing the infected cells until about 100% confluent;
(d) subculturing the cells of step (c), wherein subculturing comprises seeding at least a portion of the cells onto a mouse embryonic fibroblast (MEF) feeder cell layer;
(e) expanding the cells seeded onto the feeder layer of step (d) for a period of time sufficient to produce a population of cells which produce glucagon and which express a pancreatic alpha cell marker gene selected from the group consisting of CGC, CNTN1, PCSK1, PDK4, RGS4, IRX2, LPPR4, LOXL2, KCTD12, KL, and any combination thereof.
US Pat. No. 10,426,816

METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY TRACT INFECTIONS

Institut National de la S...

1. A method of treating an acute respiratory tract infection comprising administering to a subject that has an acute respiratory tract infection caused by Streptococcus pneumonia a therapeutically effective amount of a TLR5 agonist, wherein the TLR5 agonist consists of a flagellin polypeptide, and wherein said TLR5 agonist is administered topically by intranasal administration or pulmonary administration.
US Pat. No. 10,428,352

METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION

The Regents of the Univer...

1. A method of targeting and binding a target DNA in a prokaryotic cell, the method comprising:contacting the target DNA inside of the prokaryotic cell with:
(a) a Cas9 protein; and
(b) a single molecule DNA-targeting RNA comprising, in 5? to 3? order:
(i) a targeter-RNA comprising a nucleotide sequence that is complementary to, and hybridizes with, a target sequence of the target DNA; and
(ii) an activator-RNA that hybridizes with the targeter-RNA to form a double-stranded RNA duplex,
wherein (i) and (ii) are covalently linked by intervening nucleotides,
wherein the Cas9 protein and the single molecule DNA-targeting RNA form a complex that binds to the target DNA.
US Pat. No. 10,429,379

AUTOANTIGENS FOR DIAGNOSIS OF RHEUMATOID ARTHRITIS

THE GENERAL HOSPITAL CORP...

1. A method of treating rheumatoid arthritis in a subject comprising:(a) receiving the results of an assay that indicates an increase in the level of IFN? secretion and/or T cell proliferation following contact of a biological sample from the subject with one or more of filamin-A and N-acetylglucosamine-6-sulfatase whole protein or polypeptide fragments compared with an appropriate control sample; or
(b) receiving the results of an assay that indicates an increase in the level of immunocomplexes following contact of a biological sample from the subject with one or more of filamin-A and N-acetylglucosamine-6-sulfatase, whole protein or polypeptide fragments compared to an appropriate control sample; and
(c) administering to the subject one or more of a nonsteroidal anti-inflammatory drug (NSAIDs), a steroid, a disease modifying anti-rheumatic drug (DMARD), adalimumab, etanercept, abatacept, anakinra, cimzia, golimumab, infliximab, tocilizumab and tofacitinib.
US Pat. No. 10,426,817

TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER EYE DISEASES WITH APOLIPOPROTEIN MIMETICS

MacRegen, Inc., San Jose...

1. A method of treating age-related macular degeneration (AMD), comprising administering to a human subject afflicted with AMD a therapeutically effective amount of an apolipoprotein (apo) mimetic, wherein the apo mimetic is administered locally to, into, in or around the eye in a total dose from 1 mg±10% to 10 mg±10% over a period of 6 months.
US Pat. No. 10,428,353

PRODUCTION OF PRODUCTS WITH FAVOURABLE GHG EMISSION REDUCTIONS FROM CELLULOSIC FEEDSTOCKS

Iogen Corporation, Ottaw...

1. A process for producing a transportation or heating fuel comprising the steps of:(i) treating a cellulosic feedstock in one or more processing steps that release extractives comprising acetic acid, acetate or a combination thereof from the feedstock;
(ii) conducting a solids-liquid separation on a process stream comprising the extractives and solids, thereby producing an aqueous stream comprising the extractives and a solids stream comprising insoluble components;
(iii) feeding at least a portion of the aqueous stream comprising one or more of the extractives to an anaerobic digester to produce a crude biogas that comprises carbon dioxide;
(iv) removing at least 80 wt % of the carbon dioxide present in the crude biogas to produce a purified biogas;
(v) carrying out or causing one or more parties to carry out a process comprising subjecting solids from at least one stream selected from the solids stream comprising the insoluble components and a stream derived therefrom to a thermal process to produce a fuel or fuel intermediate;
(vi) introducing the purified biogas produced in step (iv) to a pipeline and causing withdrawal of an amount of methane from said pipeline corresponding to an amount of the purified biogas introduced to the pipeline;
(vii) providing one or more products obtained or derived from step (v), step (vi) or a combination thereof for use as a transportation or heating fuel; and
(viii) generating or causing generation of a renewable fuel credit with respect to said one or more products.
US Pat. No. 10,429,380

DEVICE COMPRISING A HYDROGEL HAVING A GLUCOSE-BINDING PROTEIN AND A LIGAND OF THE GLUCOSE-BINDING PROTEIN INCORPORATED THEREIN

EyeSense AG, Basel (CH)

1. A device comprising a hydrogel having a glucose-binding protein and a ligand of the glucose-binding protein incorporated therein, wherein the hydrogel comprises:(a) a first hydrogel matrix made of alginate; and
(b) a second hydrogel matrix which forms an interpenetrating network within the first hydrogel matrix, wherein the second hydrogel matrix is formed simultaneously with or sequentially to the first hydrogel matrix, and wherein the first and second hydrogel matrix cannot be separated unless covalent bonds or ionic bonds are broken.
US Pat. No. 10,426,818

METHOD AND PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF DIABETES

INSERM (Institut National...

1. A method for treating type 2 diabetes comprisingadministering to a human subject in need thereof a therapeutically effective amount of (Pyr1)-apelin-13.
US Pat. No. 10,428,098

PROCESSES FOR PREPARING AND USING RUTHENIUM AND OSMIUM COMPLEXES

Johnson Matthey Public Li...

2. A process for preparing an [M(Y)2(L)2(L2)] complex, the process comprising the step of:reacting an [M(Y)2(L)2] complex with L2 in a polar aprotic solvent;
wherein:
M is ruthenium or osmium;
Y is a carboxylate ligand;
L is a monodentate phosphorus ligand; and
L2 is a bidentate N,N ligand comprising two nitrogen-containing groups.
US Pat. No. 10,428,354

ALTERED HOST CELL PATHWAY FOR IMPROVED ETHANOL PRODUCTION

DANISCO US INC, Palo Alt...

1. A recombinant yeast cell comprising at least one heterologous nucleic acid encoding one or more polypeptide having:i) phosphoketolase activity;
ii) phosphotransacetylase activity; and
iii) acetylating acetaldehyde dehydrogenase activity,
wherein said cell does not comprise a heterologous modified xylose reductase gene,
wherein said cell is capable of increased ethanol production from glucose in a fermentation process when compared to the yeast cell without the at least one heterologous nucleic acid, and
wherein the polypeptide having phosphoketolase activity has the amino acid of SEQ ID NO: 57, the polypeptide having acetylating acetaldehyde dehydrogenase activity has the amino acid of SEQ ID NO: 32, and the polypeptide having phophotransacetylase activity is the phophotransacetylase from Lactobacillus plantarum.

US Pat. No. 10,433,294

METHOD AND DEVICE FOR TRANSMITTING/RECEIVING SIGNAL OF V2X TERMINAL IN WIRELESS COMMUNICATION SYSTEM

LG ELECTRONICS INC., Seo...

1. A method of transmitting a synchronization signal in a wireless communication system, the method comprising:generating a secondary synchronization signal; and
transmitting the generated secondary synchronization signal,
wherein the secondary synchronization signal is transmitted only in subframe 5 among subframe 0 to subframe 9, when the secondary synchronization signal is transmitted by a V-UE (vehicle user equipment), and
wherein the secondary synchronization signal is transmitted only in the subframe 0 among the subframe 0 to the subframe 9, when the secondary synchronization signal is transmitted by a D2D (Device-to-Device) UE.

US Pat. No. 10,433,292

LTE CHANNEL ACCESS OVER UNLICENSED BANDS

QUALCOMM Incorporated, S...

12. A base station for wireless communications, comprising:a processor;
memory in electronic communication with the processor; and
instructions stored in the memory, the instructions being executable by the processor to:
perform a clear channel assessment (CCA) at the base station associated with a first radio access technology (RAT) to determine availability of a shared spectrum,
transmit, by the base station, a first waveform to user equipments (UEs) associated with the first RAT over the shared spectrum when a determination is made that the shared spectrum is available, the first waveform comprising a first component configured to be readable by a first device associated with a second RAT different from the first RAT and a second component configured to be readable by a second device associated with the first RAT, the first component comprising a first allocation of resources for the second RAT and the second component comprising a second allocation of resources for the first RAT; and
receive, at the base station, a second waveform from one or more of the UEs associated with the first RAT, the second waveform being transmitted responsive to the first waveform and being received over the shared spectrum and being configured to indicate that the respective UE has channel access over the shared spectrum to receive data from the base station.

US Pat. No. 10,433,291

DISCOVERY REFERENCE SIGNAL TRANSMISSION WINDOW DETECTION AND DISCOVERY REFERENCE SIGNAL MEASUREMENT CONFIGURATION

QUALCOMM Incorporated, S...

1. A method of wireless communication comprising:receiving a user equipment (UE) measurement report from a UE that includes information regarding a discovery reference signal (DRS) of a neighbor cell;
determining, based at least in part on the UE measurement report, one or more parameters associated with a DRS transmission window of the neighbor cell; and
transmitting a message that includes a DRS measurement timing configuration (DMTC) to the UE, wherein the DMTC is based at least in part on the one or more parameters associated with the DRS transmission window of the neighbor cell determined based at least in part on the UE measurement report.

US Pat. No. 10,433,290

UPLINK CONTROL INFORMATION TRANSMISSION METHOD AND APPARATUS IN CARRIER AGGREGATION

Huawei Technologies Co., ...

1. A method for sending information in a communications system, comprising:receiving, by a user equipment (HE), a radio resource control (RRC) configuration signaling from a base station carrying indication information instructing the HE to perform spatial bundling on hybrid automatic repeat request (HARQ) acknowledgement/negative acknowledgement (ACK/NACK) information, wherein the spatial bundling is an AND logical operation on the HARQ ACK/NACK information, and the HARQ ACK/NACK information comprises two bits corresponding to two codewords of a carrier;
performing, by the UE, according to the indication information, the spatial bundling on the HARQ ACK/NACK information by performing the AND logical operation on the two bits of the HARQ ACK/NACK information to determine bundled HARQ information, wherein the bundled HARQ information comprises 1-hit ACK/NACK information; and
sending, by the HE, the bundled HARQ information on a physical uplink control channel (PUCCH) resource.

US Pat. No. 10,433,289

COMMUNICATION APPARATUS AND COMMUNICATION METHOD WHICH UTILIZES A FIRST FRAME INCLUDING WIRELESS COMMUNICATION RESOURCE INFORMATION AND ATTRIBUTE INFORMATION

SONY CORPORATION, Tokyo ...

1. A communication apparatus, comprising:communication circuitry configured to:
transmit a first frame comprising wireless communication resource information in which resources selectable as uplink resources are specified from a plurality of resources and attribute information related to transmission of a second frame; and
receive the second frame transmitted as a response to the first frame,
wherein the second frame is transmitted using at least one resource selected from the selectable resources specified in the first frame on the basis of the attribute information, and
wherein the resource information comprises information related to a frequency resource and information related to a spatial stream.

US Pat. No. 10,433,285

METHOD AND APPARATUS FOR CONTROLLING A ELECTRONIC DEVICE IN A COMMUNICATION SYSTEM

Samsung Electronics Co., ...

1. A first electronic device for executing a control command, the first electronic device comprising:a communication interface configured to communicate with a second electronic device or a server;
a memory configured to store a grouping table, wherein the grouping table is configured by mapping each control command with at least one second electronic device, and each of the control commands is to be executed by a mapped second device; and
a controller configured to:
receive a control command from the server, wherein the control command is one of a silent mode transition command, a vibration mode transition command, airplane mode transition command, or a display brightness adjustment command;
identify whether the received control command is in the grouping table;
identify whether the first electronic device is a master electronic device, in case of the received control command being in the grouping table;
transmit the control command to the at least one second electronic device mapped to the control command, in case of the first electronic device being the master electronic device; and
execute the received control command, in case of the first electronic device being the master electronic device.

US Pat. No. 10,433,284

BEARER MANAGEMENT FOR PROSE DIRECT DISCOVERY

QUALCOMM Incorporated, S...

1. A method for wireless communications, comprising:sending, from a user equipment (UE), a connection request that indicates a service type and that includes an information element (IE), wherein the IE indicates at least one bearer of a set of bearers that is to be suspended for communications of the indicated service type and an evolved packet system (EPS) bearer context status IE that indicates a subset of EPS bearers of the set of bearers that are to be active and the connection request comprises an extended service request (ESR) indicating the service type and wherein the IE comprises the evolved packet system (EPS) bearer context status IE that indicates a subset of EPS bearers of the set of bearers that are to be active and an extended service request (ESR) indicating the service type;
establishing the set of bearers;
suspending at least one bearer of the set of bearers after sending the connection request, the at least one suspended bearer comprising the at least one bearer indicated by the IE included in the connection request sent by the UE;
receiving, at the UE, a message in response to the ESR that establishes at least one radio bearer corresponding to a respective EPS bearer of the subset indicated by the EPS bearer context status IE to be active, and wherein suspending comprises locally suspending each EPS bearer of the set of bearers for which no corresponding radio bearer is established;
sending, from the UE, a second ESR that indicates a second service type and includes a second EPS bearer context status IE that indicates a second subset of EPS bearers of the set of bearers that are to be active;
receiving, at the UE, a second message in response to the second ESR that establishes at least one radio bearer, each radio bearer corresponding to a respective EPS bearer indicated by the second EPS bearer context status IE to be active; and
activating from suspension each respective EPS bearer for which a corresponding radio bearer is established.

US Pat. No. 10,433,283

SYSTEM AND METHOD FOR BANDWIDTH DIVISION AND RESOURCE BLOCK ALLOCATION

Huawei Technologies Co., ...

1. A method comprising:transmitting a bandwidth portion assignment to indicate an assignment of at least one first bandwidth portion of a plurality of bandwidth portions within an available bandwidth to a given first numerology, the given first numerology having an associated first OFDM subcarrier spacing and first symbol duration, the plurality of bandwidth portions having at least one second bandwidth portion that is assigned to a second numerology, the second numerology having an associated second OFDM subcarrier spacing and second symbol duration, and the first OFDM subcarrier spacing differing from the second OFDM subcarrier spacing by a factor of 2n, where n?0.

US Pat. No. 10,433,282

NARROW BANDWIDTH OPERATION IN LTE

QUALCOMM Incorporated, S...

1. A method of wireless communication, comprising:transmitting wideband downlink information to a first set of user equipments (UEs), the wideband downlink information comprising control information and data;
determining a starting symbol of an effective data region for narrowband downlink information for a second set of UEs, the starting symbol selected from a plurality of symbols, such that the starting symbol is semi-statically configured, and the starting symbol indicated to the second set of UEs prior to transmitting the narrowband downlink information;
disabling intra-subframe hopping and/or inter-subframe hopping to maintain narrowband transmissions for the second set of UEs; and
transmitting the narrowband downlink information to the second set of UEs operating in a narrower bandwidth than a bandwidth of the first set of UEs, the narrowband downlink information comprising control information and data.

US Pat. No. 10,433,279

METHOD OF RECEIVING SINGLE-CELL MULTICAST DATA AND APPARATUS FOR SAME

KT CORPORATION, Gyeonggi...

1. A method of receiving single-cell multicast data by a user equipment (UE), the method comprising:receiving carrier information for Single Cell-Multicast Control Channel (SC-MCCH) reception through system information;
monitoring SC-MCCH scheduling information on a physical downlink control channel (PDCCH) based on the carrier information; and
receiving an SC-MCCH on a physical downlink shared channel (PDSCH) based on the monitored SC-MCCH scheduling information,
wherein the UE is configured to access a network service having a channel bandwidth limited to about 200 kHz or lower or to operate in a bandwidth limited to 6 physical resource blocks (PRBs),
wherein the SC-MCCH scheduling information is identified using a Single-Cell Radio Network Temporary Identifier (SC-RNTI), and
wherein the system information corresponds to system information block type 20 (SystemInformationBlockType20).

US Pat. No. 10,433,278

METHODS AND DEVICE FOR ALLOCATING AND PROCESSING SUB-FRAME RESOURCE

1. A method for allocating sub-frame resource, comprising:under the condition that a Multicast Channel (MCH) Scheduling Period (MSP) exceeds a Common Sub-frame allocation Period (CSP), determining an allocation manner for allocating Multicast Broadcast over Single Frequency Network (MBSFN) sub-frame resources to each MCH and a Multimedia Broadcast Multicast Service (MBMS) in the MCH; and
notifying User Equipment (UE) of the allocation manner;
wherein determining the allocation manner for allocating the MBSFN sub-frame resources to each MCH and the MBMS in the MCH comprises:
allocating the MBSFN sub-frame resources for the MBMSs to each MCH in the MSP; and when a number of MBSFN sub-frames allocated to a part of MCHs in the MSP exceeds a preset threshold value, adding indication information to a corresponding position where the number of the MBSFN sub-frames allocated to the part of MCHs reaches the preset threshold value, and starting recounting of other MBSFN sub-frames after the position, wherein a number of the other MBSFN sub-frames is a difference value between a number of all MBSFN sub-frames comprised in the MBSFN sub-frame resources and the preset threshold value, and if the number of the other MBSFN sub-frames still exceeds the preset threshold value, indication information is added to corresponding positions where the preset threshold value is reached every time and the other MBSFN sub-frames after the positions are recounted until the number of the other MBSFN sub-frames is lower than the preset threshold value; or
allocating the MBSFN sub-frame resources for the MBMSs to each MCH in the MSP; and when a number of MBSFN sub-frames allocated to a part of MCHs in the MSP exceeds a preset threshold value, starting recounting of other MBSFN sub-frames after a corresponding position where the number of the MBSFN sub-frames allocated to the part of MCHs reaches the preset threshold value according to an agreement premade with the UE, wherein a number of the other MBSFN sub-frames is a difference value between a number of all MBSFN sub-frames comprised in the MBSFN sub-frame resources and the preset threshold value, and if the number of the other MBSFN sub-frames still exceeds the preset threshold value, the other MBSFN sub-frames after corresponding positions where the preset threshold value is reached every time are recounted until the number of the other MBSFN sub-frames is lower than the preset threshold value, and when a number of MBSFN sub-frames allocated to a single MBMS exceeds the preset threshold value, other MBSFN sub-frames after corresponding positions where the preset threshold value is reached every time are recounted.

US Pat. No. 10,433,275

SYSTEMS AND METHODS FOR POSITIONING MOBILE DEVICES IN A FIFTH GENERATION WIRELESS NETWORK

QUALCOMM Incorporated, S...

1. A method at a user equipment (UE) for supporting location of the UE with 3rd Generation Partnership Project (3GPP) Fifth Generation (5G) New Radio (NR) wireless access, the method comprising:receiving a first Long Term Evolution (LTE) Positioning Protocol (LPP) message from a location server, wherein the first LPP message comprises a location request and is received via a serving 5G base station;
obtaining at least one location measurement based on the first LPP message, wherein the at least one location measurement comprises a measurement for a Radio Access Technology (RAT)-independent position method or a measurement for an Evolved Universal Terrestrial Radio Access (E-UTRA) position method;
determining location information based on the at least one location measurement; and
sending a second LPP message to the location server, wherein the second LPP message comprises the location information and is sent via the serving 5G base station.

US Pat. No. 10,433,273

METHOD AND APPARATUS FOR UTILIZING MOBILE SUBSCRIBER IDENTIFICATION INFORMATION WITH MULTIPLE DEVICES BASED ON REGISTRATION REQUESTS

1. A network server, comprising:a processing system including a processor; and
a memory that stores executable instructions that, when executed by the processing system, facilitate performance of operations, comprising:
receiving a first international mobile subscriber identity associated with a registration request that is directed to a registration function server by a first communication device;
determining that the first international mobile subscriber identity is included in a group of international mobile subscriber identities that are shared with other communication devices, wherein the group of international mobile subscriber identities are configured to be utilized in registration for communication services;
determining that the first communication device is not associated with a particular location; and
reassigning, via an over-the-air interface, a second international mobile subscriber identity to the first communication device, wherein the over-the-air interface utilizes a transport key that is stored by the first communication device and is not stored by a second communication device that shares the first international mobile subscriber identity.

US Pat. No. 10,433,271

METHOD AND APPARATUS FOR MAINTAINING UPLINK SYNCHRONIZATION AND REDUCING BATTERY POWER CONSUMPTION

InterDigital Technology C...

1. A method performed by a wireless transmit/receive unit (WTRU), the method comprising:receiving discontinuous reception (DRX) control information from a wireless network, the DRX control information indicating a time interval that the WTRU should monitor a downlink control channel;
receiving a control message on the downlink control channel while monitoring the downlink control channel according to the DRX control information, wherein the control message is associated with an identifier of the WTRU, the control message indicating that the WTRU should transmit a random access preamble to the wireless network;
transmitting the random access preamble to the wireless network in response to receiving the control message; and
receiving a timing adjustment command from the wireless network.

US Pat. No. 10,433,270

SYNCHRONIZATION FOR BATTERY POWERED IOT NETWORKS

Verizon Patent and Licens...

1. A method comprising:identifying, by an Internet of Things (IoT) device, a plurality of IoT devices associated with a wireless IoT network, wherein the IoT device is configured as a coordinator for the wireless IoT network;
determining, by the IoT device, a clock error rate associated with the wireless IoT network;
determining, by the IoT device, a last synchronization time;
determining, by the IoT device, a data time period during which one or more of the plurality of IoT devices are expected to send data to the IoT device;
setting, by the IoT device, a wakeup time period for the IoT device based on the determined clock error rate, the determined last synchronization time, and the determined data time period;
entering, by the IoT device, a sleep mode;
exiting, by the IoT device, the sleep mode when the wakeup time period begins; and
performing, by the IoT device, a clock synchronization between the IoT device and at least one of the plurality of IoT devices during the wakeup time period.

US Pat. No. 10,433,269

METHOD AND SYSTEM FOR INTEGRATED BACKHAUL AND WIRELESS ACCESS NETWORK

Samsung Electronics Co., ...

1. A relay node (RN) comprising:a transceiver configured to receive, from a second node, a synchronization signal burst comprising a plurality of synchronization signal blocks, each of the plurality of synchronization signal blocks transmitted using a set of channel resources; and
a processor operably connected to the transceiver, the processor configured to:
measure the received plurality of synchronization signal blocks;
identify, based at least in part on measurement of the plurality of synchronization signal blocks, at least one of the plurality of synchronization signal blocks to monitor as a synchronization reference for the second node; and
select a set of channel resources for use to transmit an RN synchronization signal to at least one third node, the selected set of channel resources comprising at least one other synchronization signal block from the synchronization signal burst.

US Pat. No. 10,433,268

CALCULATING TIMING OFFSET IN WIRELESS COMMUNICATIONS

Telefonaktiebolaget LM Er...

1. A method of operation of a device in a cellular communications network, the method comprising:detecting a timing signal from a serving base station;
obtaining timing information from at least one other base station;
setting a value for a transmission time offset based on the detected timing signal from the serving base station and the timing information obtained from the at least one other base station; and
transmitting signals to the serving base station using the set value for the transmission time offset, wherein transmitting the signals to the serving base station comprises transmitting the signals to the serving base station with a power that is determined based on an uncertainty in the set value for the transmission time offset.

US Pat. No. 10,433,267

SATELLITE LINK BUDGET COMMAND INTERFACE TOOL

The Boeing Company, Chic...

1. A method for commanding a space vehicle (SV), the method comprising:determining, by at least one processor, a transmitter output power for a control word (CW) at a particular temperature for a transmitter on the SV,
wherein the particular temperature of the transmitter is a temperature prediction based on on-orbit operations;
generating, by the at least one processor, a transmitter uplink command by using the transmitter output power;
transmitting, by at least one antenna, a transmitter uplink command signal comprising the transmitter uplink command to the SV; and
adjusting the transmitter to provide an output power according to the transmitter uplink command.

US Pat. No. 10,433,265

METHOD FOR CONTROLLING TRANSMISSION POWER OF SOUNDING REFERENCE SIGNAL IN WIRELESS COMMUNICATION SYSTEM AND APPARATUS FOR SAME

LG Electronics Inc., Seo...

1. A method for a user equipment (UE) to transmit a sounding reference signal to a base station in a wireless communication system supporting eIMTA (Enhanced Interference Management and Traffic Adaptation), the method comprising:receiving a higher layer signaling regarding configuration of a first subframe set and a second subframe set; and
transmitting the sounding reference signal to the base station on subframe ‘i’,
wherein the ‘i’ is a subframe number and an integer equal to or greater than 0,
wherein transmission power of the sounding reference signal transmitted on the subframe ‘i’ is determined based on fc(i) for the first subframe set, and fc(0)(i) for the second subframe set,
wherein the fc(i) is a current physical uplink shared channel (PUSCH) power control adjustment state for serving cell ‘c’ in subframe ‘i’ belonging to the first subframe set, and the)fc(0)(i) is a current PUSCH power control adjustment state for serving cell ‘c’ in subframe ‘i’ belonging to the second subframe set, and
wherein the fc(i) is separately accumulated from a value of a previous subframe belonging to the first subframe set while the fc(0)(i) is separately accumulated from a value of a previous subframe belonging to the second subframe.

US Pat. No. 10,433,264

COMMUNICATION CONTROL DEVICE, TRANSMISSION POWER ALLOCATION METHOD AND PROGRAM

Sony Corporation, (JP)

1. A node for controlling power allocated within a network, the node being a master in the network, and the network having a plurality of channels used by a primary system for communication, the node comprising:a first communication interface comprising an interface between the node and a server;
a second communication interface comprising one or more wireless interfaces between the node and respective ones of one or more other nodes, the one or more other nodes being slaves of the node;
a memory in which a program is stored; and
a processor to operate according to the program stored in the memory to:
receive from the server information indicating transmission power allocation for one or more of the plurality of channels selected for use as part of a secondary system, the transmission power allocation being dependent on a path loss between a reference point of the primary system and the secondary system, the path loss being dependent on a distance between the reference point of the primary system and the secondary system and on one or more frequencies respectively allocated to the one or more of the plurality of channels selected for use as part of the secondary system, and the reference point being determined according to position data for a service area of the primary system and being a point at which interference in the primary system due to the secondary system is the harshest, and
set the transmission power of the node within a transmission power range indicated by the received information indicating transmission power allocation.

US Pat. No. 10,433,261

SELF-OPTIMIZING DISTRIBUTED ANTENNA SYSTEM USING SOFT FREQUENCY REUSE

Dali Systems Co., Ltd., ...

1. A method of determining a transmission power of a digital remote unit (DRU) in a distributed antenna system (DAS), the method comprising:a) setting a transmission power level for the DRU;
b) determining a key performance indicator related to a number of satisfied users at the transmission power;
c) iteratively adjusting a transmission power level for the DRU to increase the key performance indicator related to the number of satisfied users; and
d) setting the transmission power level for the DRU at an iterated power level.

US Pat. No. 10,433,260

ANTENNA-PARAMETER CONTROL IN A DISTRIBUTED SYSTEM

ARRIS Enterprises LLC, S...

1. An electronic device, comprising:one or more antenna nodes configured to couple, via a cable having a length, to an antenna module; and
an interface circuit communicatively coupled to the one or more antenna nodes, wherein the electronic device is configured to:
provide, via the interface circuit, electrical signals intended for the antenna module, wherein the electrical signals correspond to an output transmit-power level at the interface circuit;
receive, via the interface circuit, feedback from the antenna module about an input transmit-power level at the antenna module and an orientation of an antenna in the antenna module;
determine a modified output transmit-power level based on the input transmit-power level at the antenna module and the orientation; and
provide, via the interface circuit, modified electrical signals intended for the antenna module, wherein the modified electrical signals correspond to the modified output transmit-power level at the interface circuit.

US Pat. No. 10,433,258

METHOD AND APPARATUS FOR TRANSMITTING CONTROL INFORMATION IN A WIRELESS COMMUNICATION SYSTEM

LG ELECTRONICS INC., Seo...

1. A method for transmitting a physical uplink control channel (PUCCH) signal by a user equipment (UE) in a wireless communication system, the method comprising:generating control information including hybrid automatic repeat request acknowledgement (HARQ-ACK) bit(s) and a scheduling request (SR) bit;
setting a transmit power for the PUCCH signal based on a parameter nSR; and
transmitting the PUCCH signal including the control information based on the transmit power at a subframe configured for SR transmission,
wherein nSR is a parameter having a value of 0 or 1 based on whether or not the UE has any associated transport block for an uplink shared channel (UL-SCH) with regard to the subframe.

US Pat. No. 10,433,257

POWER CONTROL METHOD AND APPARATUS FOR UPLINK CONTROL CHANNEL

Huawei Technologies Co., ...

16. A network device, comprising:a processor; and
a memory coupled to the processor, storing processor-readable instructions which when executed causes the processor to implement operations including:
determining that user equipment is to send first uplink control information on a first physical uplink control channel (PUCCH) and in a subframe i, wherein the first uplink control information comprises channel state information (CSI), a hybrid automatic repeat request-acknowledgment (HARQ-ACK), and/or a scheduling request (SR);
determining transmit power for sending the first uplink control information on the first PUCCH and in the subframe i, wherein the transmit power is a sum of a base power adjustment value and any one of a first power adjustment value, a second power adjustment value, a third power adjustment value, a fourth power adjustment value, or a fifth power adjustment value; and
receiving the first uplink control information that is sent by the user equipment on the first PUCCH by using power that is not greater than the transmit power, wherein
(a) the first power adjustment value is a power adjustment value determined by the user equipment according to a quantity of bits of the first uplink control information,
(b) the second power adjustment value is a power adjustment value determined by the user equipment according to the quantity of the bits of the first uplink control information and a quantity of resources of the first PUCCH,
(c) the third power adjustment value is a power adjustment value determined by the user equipment according to the quantity of the resources of the first PUCCH and a ratio of the quantity of the bits of the first uplink control information to the quantity of the resources of the first PUCCH,
(d) the fourth power adjustment value is a power adjustment value determined by the user equipment according to the quantity of the resources of the first PUCCH, and
(e) the fifth power adjustment value is a power adjustment value determined by the user equipment according to the quantity of the resources of the first PUCCH and a ratio of a quantity of bits of second uplink control information to a quantity of resources occupied on the first PUCCH by the second uplink control information, or the fifth power adjustment value is a power adjustment value determined by the user equipment according to the quantity of the resources of the first PUCCH and a ratio of a quantity of bits of the second uplink control information to the quantity of the resources of the first PUCCH, wherein the second uplink control information is a subset of the first uplink control information; and
the base power adjustment value comprises a sum of PO_PUCCH and PLc, or the base power adjustment value comprises a sum of PO_PUCCH and ?c·PLc, wherein
PO_PUCCH is a value configured for the user equipment by the network device using higher layer signaling;
PLc is a path loss that is determined by the user equipment and that is of a downlink of a cell c in which the first PUCCH is located; and
?c is a path loss factor that is configured for the user equipment by the network device and that is of the cell c in which the first PUCCH is located.